




Application 10/593133

1) Please, search for the following species and post result in a separate sheet



2) Please, search for claim 1

1. (Currently amended) A compound of formula (I) or a pharmaceutically, vетеринарно or agriculturally acceptable salt or solvate thereof.



wherein:

Please, place the result in a separate sheet.

Because I am currently learning how to perform structure search, I would very much like to learn how you decide your search strategy.
You can contact me for a quick chat about it, if you have time.

Thank you so much.

Valerie

Author Search

=> FILE HCPLUS

FILE 'HCPLUS' ENTERED AT 13:33:18 ON 16 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Apr 2009 VOL 150 ISS 16

FILE LAST UPDATED: 15 Apr 2009 (20090415/ED)

HCplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.


CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCPLUS' FILE


=> D STAT QUE L26
L9 STR



Structure attributes must be viewed using STN Express query preparation.

L12 2562 SEA FILE=REGISTRY SSS FUL L9

L14 STR



Structure attributes must be viewed using STN Express query preparation.

L17 263 SEA FILE=REGISTRY SUB=L12 SSS FUL L14
 L18 42 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L17
 L19 STR

Structure attributes must be viewed using STN Express query preparation:
 Uploading strL19.str

L21 2 SEA FILE=REGISTRY SUB=L12 SSS FUL L19
 L22 1 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L21
 L23 24 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON CRITCHER D?/AU
 L24 28 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON WALSHE N?/AU
 L25 29 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON LAURET C?/AU
 L26 1 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON (L23 OR L24 OR L25)
 AND (L18 OR L22)

=> FILE WPIX
 FILE 'WPIX' ENTERED AT 13:33:26 ON 16 APR 2009
 COPYRIGHT (C) 2009 THOMSON REUTERS

FILE LAST UPDATED: 9 APR 2009 <20090409/UP>
 MOST RECENT UPDATE: 200923 <200923/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
 >>> Now containing more than 1.3 million chemical structures in DCR <<

>>> IPC and US National Classifications have been updated
 with reclassifications to the end of 2008.
 ECLA, F-Term and FI-Term classifications are complete
 to the end of 2008.
 No update date (UP) has been created for the reclassified
 documents, but they can be identified by
 specific update codes (see HELP CLA for details)<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
 PLEASE VISIT:
http://www.stn-international.com/stn_guide.html

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

<http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/>

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/DWPAnaVist2_0608.html

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

'BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> D STAT QUE L31
 L19 STR

Structure attributes must be viewed using STN Express query preparation:
 Uploading strL19.str
 Uploading strL29.str

L23 24 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON CRITCHER D?/AU
 L24 28 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON WALSHE N?/AU
 L25 29 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON LAURET C?/AU
 L29 2 SEA FILE=WPIX SSS FUL L19
 L30 1 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L29/DCR
 L31 1 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (L23 OR L24 OR L25) AND
 L30

=> DUP REM L26 L31
 FILE 'HCAPLUS' ENTERED AT 13:33:38 ON 16 APR 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 13:33:38 ON 16 APR 2009
 COPYRIGHT (C) 2009 THOMSON REUTERS
 PROCESSING COMPLETED FOR L26
 PROCESSING COMPLETED FOR L31
 L38 1 DUP REM L26 L31 (1 DUPLICATE REMOVED)
 ANSWER '1' FROM FILE HCAPLUS

=> D IBIB ED ABS HITSTR L38

L38 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 1
 ACCESSION NUMBER: 2005:1042223 HCAPLUS Full-text
 DOCUMENT NUMBER: 143:347161
 TITLE: Preparation of N-(1-arylpypyrazol-4-yl) sulfonamides as
 parasiticides
 INVENTOR(S): Critcher, Douglas James; Lauret,
 Christelle; Walshe, Nigel Derek Arthur
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl., 158 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090313	A1	20050929	WO 2005-IB597	20050307
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,			

(Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of N-(1-arylpyrazol-4-yl) sulfonamides as parasiticides)


RN 865832-38-8 HCPLUS

CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(methylsulfonyl)- (CA INDEX NAME)




RN 865832-40-2 HCPLUS

CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-[(methylthio)methyl]- (CA INDEX NAME)




RN 865832-43-5 HCPLUS

CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(methylsulfonyl)- (CA INDEX NAME)




RN 865832-44-6 HCPLUS

CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 865832-49-1 HCAPLUS

CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-1,1,1-trifluoro-N-methyl- (CA INDEX NAME)




RN 865832-55-9 HCAPLUS

CN Sulfur, [4-[5-amino-4-[bis(methylsulfonyl)amino]-3-cyano-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-57-1 HCAPLUS

CN Methanesulfonamide, N-[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(methylsulfonyl)- (CA INDEX NAME)




RN 865832-59-3 HCPLUS

CN Methanesulfonamide, N-[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 865832-61-7 HCPLUS

CN Sulfur, [4-[5-amino-3-cyano-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-64-0 HCPLUS

CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]-N-(methylsulfonyl)- (CA INDEX NAME)




RN 865832-67-3 HCPLUS

CN Sulfur, [4-[5-amino-3-cyano-4-[(methylsulfonyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-95-7 HCPLUS

CN Sulfur, [4-[4-[bis(methylsulfonyl)amino]-3-cyano-5-methoxy-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-96-8 HCPLUS

CN Sulfur, [4-[4-[bis(methylsulfonyl)amino]-3-cyano-5-[(dimethylamino)methylene]amino-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-00-7 HCPLUS

CN Sulfur, [4-[4-[bis(methylsulfonyl)amino]-3-cyano-5-[(2-(1-piperidinyl)ethyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-04-1 HCPLUS

CN Sulfur, [4-[5-amino-3-cyano-4-[[[[1,1-dimethylethoxy]carbonyl]amino]sulfonyl]amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)



RN 865833-20-1 HCAPLUS

CN Sulfur, [4-[4-[bis(methylsulfonyl)amino]-3-cyano-5-[(2-(dimethylamino)ethyl)methylamino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




IT 865832-30-0P 865832-31-1P 865832-32-2P
 865832-33-3P 865832-34-4P 865832-35-5P
 865832-36-6P 865832-37-7P 865832-39-9P
 865832-41-3P 865832-42-4P 865832-45-7P
 865832-46-8P 865832-47-9P 865832-48-0P
 865832-50-4P 865832-51-5P 865832-52-6P
 865832-53-7P 865832-54-8P 865832-56-0P
 865832-58-2P 865832-60-6P 865832-62-8P
 865832-63-9P 865832-65-1P 865832-66-2P
 865832-68-4P 865832-69-5P 865832-70-8P
 865832-71-9P 865832-72-0P 865832-74-2P
 865832-75-3P 865832-76-4P 865832-77-5P
 865832-78-6P 865832-79-7P 865832-80-0P
 865832-81-1P 865832-82-2P 865832-83-3P
 865832-84-4P 865832-85-5P 865832-86-6P
 865832-87-7P 865832-88-8P 865832-89-9P
 865832-90-2P 865832-91-3P 865832-92-4P
 865832-93-5P 865832-94-6P 865832-97-9P
 865832-98-0P 865832-99-1P 865833-01-8P
 865833-02-9P 865833-03-0P 865833-05-2P
 865833-06-3P 865833-07-4P 865833-08-5P
 865833-09-6P 865833-10-9P 865833-11-0P
 865833-12-1P 865833-13-2P 865833-14-3P
 865833-15-4P 865833-17-6P 865833-18-7P
 865833-19-8P 865834-19-1P 865834-20-4P
 1027267-86-2P

RL: AGR (Agricultural use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(1-arylpyrazol-4-yl) sulfonamides as parasiticides)


RN 865832-30-0 HCAPLUS

CN Sulfur, [4-[5-amino-3-cyano-4-[(2,2-difluoroethyl)(methylsulfonyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-31-1 HCPLUS

CN Sulfur, [4-[5-amino-3-cyano-4-{methyl[(trifluoromethyl)sulfonyl]amino}-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-32-2 HCPLUS

CN Benzenesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-3,4-difluoro- (CA INDEX NAME)




RN 865832-33-3 HCPLUS

CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 865832-34-4 HCPLUS

CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(cyanomethyl)- (CA INDEX NAME)




RN 865832-35-5 HCPLUS


CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 865832-36-6 HCAPLUS
 CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 865832-37-7 HCAPLUS
 CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 865832-39-9 HCAPLUS
 CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 865832-41-3 HCPLUS

CN Cyclopropanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(methylsulfonyl)- (CA INDEX NAME)




RN 865832-42-4 HCPLUS

CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-((dimethylamino)sulfonyl)- (CA INDEX NAME)



RN 865832-45-7 HCPLUS


CN Benzenemethanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]- (CA INDEX NAME)



RN 865832-46-8 HCPLUS


CN Ethenesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-2-phenyl-, (1E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 865832-47-9 HCPLUS

CN Sulfur, [4-[5-amino-4-[bis(methylsulfonyl)amino]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-48-0 HCPLUS


CN 1H-Pyrazole-3-carbonitrile, 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-(1,1-dioxido-2-isothiazolidinyl)- (CA INDEX NAME)




RN 865832-50-4 HCPLUS
 CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(cyclopropylmethyl)-1,1,1-trifluoro- (CA INDEX NAME)



RN 865832-51-5 HCPLUS
 CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 865832-52-6 HCPLUS
 CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-1,1,1-trifluoro-N-(methylsulfonyl)- (CA INDEX NAME)




RN 865832-53-7 HCAPLUS

CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-[(methylsulfonyl)methyl]- (CA INDEX NAME)




RN 865832-54-8 HCAPLUS

CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-cyclobutyl-1,1,1-trifluoro- (CA INDEX NAME)




RN 865832-56-0 HCAPLUS


CN Methanesulfonamide, N-[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-1,1,1-trifluoro-N-methyl- (CA INDEX NAME)




RN 865832-58-2 HCAPLUS
 CN Sulfur, [4-[4-[bis(methylsulfonyl)amino]-3-cyano-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)



RN 865832-60-6 HCAPLUS
 CN Methanesulfonamide, N-[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 865832-62-8 HCAPLUS
 CN Sulfur, [4-[5-amino-3-cyano-4-[(methylsulfonyl)[2-(1H-1,2,4-triazol-1-yl)ethyl]amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-63-9 HCAPLUS

CN Sulfur, [4-[5-amino-3-(aminocarbonyl)-4-[bis(methylsulfonyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)



RN 865832-65-1 HCAPLUS


CN Sulfur, [4-[3-acetyl-5-amino-4-(bis(methylsulfonyl)amino)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)



RN 865832-66-2 HCAPLUS


CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(difluoromethoxy)phenyl]-1H-pyrazol-4-yl]-N-(methylsulfonyl)- (CA INDEX NAME)

NAME)




RN 865832-68-4 HCPLUS

CN Sulfur, [4-[5-amino-3-cyano-4-[(methylsulfonyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-69-5 HCPLUS

CN Sulfur, [4-[5-amino-3-cyano-4-[(ethylsulfonyl)(methylsulfonyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-70-8 HCPLUS

CN Carbamic acid, [5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl](methylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 865832-71-9 HCPLUS

CN Sulfur, [4-[5-amino-3-cyano-4-[methyl(methylsulfonyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-72-0 HCPLUS

CN Sulfur, [4-[5-amino-3-cyano-4-[(2-fluoroethyl)(methylsulfonyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-74-2 HCPLUS

CN Sulfur, [4-[5-amino-4-[(2-amino-2-oxoethyl)(methylsulfonyl)amino]-3-cyano-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-75-3 HCPLUS

CN Sulfur, [4-[5-amino-3-cyano-4-[(methylsulfonyl)(1H-pyrazol-3-ylmethyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-76-4 HCPLUS

CN Sulfur, [4-[5-amino-3-cyano-4-[(methylsulfonyl)(2,2,3,3,3-pentafluoropropyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)



RN 865832-77-5 HCPLUS


CN Sulfur, [4-[5-amino-3-cyano-4-[(methylsulfonyl)ethyl]amino]-1H-pyrazol-1-yl]-3,5-dichlorophenylpentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)



RN 865832-78-6 HCPLUS

CN Sulfur, [4-[5-amino-3-cyano-4-[(methylsulfonyl)ethyl]amino]-1H-pyrazol-1-yl]-3,5-dichlorophenylpentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 865832-79-7 HCPLUS
 CN Sulfur, [4-[5-amino-3-cyano-4-[(1-methyl-1H-imidazol-2-yl)methyl](methylsulfonyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)



RN 865832-80-0 HCPLUS
 CN Sulfur, [4-[5-amino-3-cyano-4-[(5-methyl-3-isoxazolyl)methyl](methylsulfonyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-81-1 HCPLUS
 CN Sulfur, [4-[5-amino-3-cyano-4-[(2,2-dimethyl-1-oxopropyl)methyl](methylsulfonyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-82-2 HCPLUS

CN Sulfur, [4-[5-amino-3-cyano-4-[(ethyl(methylsulfonyl)amino)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)



RN 865832-83-3 HCPLUS

CN Sulfur, [4-[5-amino-3-cyano-4-[(methylsulfonyl)(phenylmethyl)amino)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-84-4 HCPLUS

CN Sulfur, [4-[5-amino-3-cyano-4-[(4-

fluorophenyl)methyl] (methylsulfonyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 865832-85-5 HCPLUS


CN Ethanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-1-(methylsulfonyl)- (CA INDEX NAME)



RN 865832-86-6 HCPLUS


CN Sulfur, [4-[5-amino-4-[bis(methylsulfonyl)amino]-3-cyano-1H-pyrazol-1-yl]-

3-chlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-87-7 HCPLUS

CN Sulfur, [4-[5-amino-3-cyano-4-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-88-8 HCPLUS

CN Sulfur, [4-[4-[bis(methylsulfonyl)amino]-3-cyano-5-[(phenylmethyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-89-9 HCPLUS

CN Sulfur, [3,5-dichloro-4-[3-cyano-5-((methoxyacetyl)amino)-4-((methylsulfonyl)(2,2,2-trifluoroethyl)amino)-1H-pyrazol-1-yl]phenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-90-2 HCPLUS

CN Sulfur, [4-[4-[(methylsulfonyl)amino]-3-cyano-5-[(ethoxymethylene)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-91-3 HCPLUS

CN Sulfur, [3,5-dichloro-4-[3-cyano-5-[(cyclopropylmethyl)amino]-4-[(methylsulfonyl)amino]-1H-pyrazol-1-yl]phenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-92-4 HCPLUS

CN Sulfur, [4-[5-(acetylamino)-3-cyano-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-93-5 HCPLUS

CN Sulfur, [3,5-dichloro-4-[3-cyano-5-methoxy-4-[(methylsulfonyl)amino]-1H-pyrazol-1-yl]phenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-94-6 HCPLUS

CN Methanesulfonamide, N-[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(methylamino)-1H-pyrazol-4-yl]-N-(methylsulfonyl)- (CA INDEX NAME)




RN 865832-97-9 HCPLUS

CN Sulfur, [4-[4-(bis(methylsulfonyl)amino)-3-cyano-5-[(2-(dimethylamino)ethyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865832-98-0 HCPLUS


CN Sulfur, [4-[4-(bis(methylsulfonyl)amino)-3-cyano-5-[(2-(1-pyrrolidinyl)ethyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)



RN 865832-99-1 HCPLUS
CN Sulfur, [4-[4-[bis(methylsulfonyl)amino]-3-cyano-5-[(2-(4-morpholinyl)ethyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-2-1) (9CI) (CA INDEX NAME)




RN 865833-01-8 HCAPLUS
CN Sulfur, [4-[5-amino-4-[bis(methylsulfonyl)amino]-3-cyclopropyl-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-02-9 HCPLUS

CN Sulfur, [4-[5-amino-4-[(methylsulfonyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-03-0 HCPLUS

CN Sulfur, [3,5-dichloro-4-[3-cyano-4-[(methylsulfonyl)amino]-5-[(4-pyridinylmethyl)amino]-1H-pyrazol-1-yl]phenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)



RN 865833-05-2 HCAPLUS
 CN Sulfur, [4-[5-amino-3-cyano-4-[(methylsulfonyl)(2-(4-pyridinyl)ethyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 865833-06-3 HCAPLUS
 CN Sulfur, [4-[5-amino-3-cyano-4-[(methylsulfonyl)(pyrazinylmethyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 865833-07-4 HCPLUS

CN Sulfur, [4-[5-amino-4-[(6-amino-3-pyridinyl)methyl](methylsulfonyl)amino]-3-cyano-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI)
(CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 865833-08-5 HCAPLUS
 CN Sulfur, [3,5-dichloro-4-[3-cyano-4-[(2-methoxy-2-oxoethyl)sulfonyl](2,2,2-trifluoroethyl)amino]-1H-pyrazol-1-yl]phenyl]pentafluoro-, (OC-6-21)-(9CI) (CA INDEX NAME)




RN 865833-09-6 HCAPLUS
 CN Sulfur, [3,5-dichloro-4-[3-cyano-5-[(2-(dimethylamino)ethyl)methylamino]-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1H-pyrazol-1-yl]phenyl]pentafluoro-, hydrochloride, (OC-6-21)-(9CI) (CA INDEX NAME)




RN 865833-10-9 HCPLUS

CN Sulfur, [3,5-dichloro-4-[3-cyano-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-5-[2-(1-piperidinyl)ethyl]amino]-1H-pyrazol-1-yl]phenyl]pentafluoro-, hydrochloride, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-11-0 HCPLUS

CN Sulfur, [4-[5-amino-4-[(aminosulfonyl)amino]-3-cyano-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-12-1 HCPLUS

CN Benzenesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-4-fluoro-N-(methylsulfonyl)- (CA INDEX NAME)




RN 865833-13-2 HCPLUS

CN Benzenesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-2,4-difluoro-N-(methylsulfonyl)- (CA INDEX NAME)




RN 865833-14-3 HCPLUS

CN Sulfur, [3,5-dichloro-4-[3-cyano-5-((methoxycarbonyl)amino)-4-((methylsulfonyl)(2,2,2-trifluoroethyl)amino)-1H-pyrazol-1-yl]phenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)



RN 865833-15-4 HCPLUS

CN Sulfur, [4-[5-[(2-aminoethyl)amino]carbonyl]amino]-3-cyano-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-17-6 HCPLUS

CN Sulfur, [4-[5-[(2-(1-azetidinyl)ethyl)amino]-3-cyano-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 865833-16-5


CMF C18 H18 Cl2 F8 N6 O2 S2



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 865833-18-7 HCPLUS
 CN Sulfur, [3,5-dichloro-4-[3-cyano-5-[(2,4-dihydroxyphenyl)methylene]amino]-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1H-pyrazol-1-yl]phenylpentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-19-8 HCPLUS
 CN Sulfur, [3,5-dichloro-4-[5-chloro-3-cyano-4-[(methylsulfonyl)(2,2,2-

trifluoroethyl)amino]-1H-pyrazol-1-yl]phenylpentafluoro-, (OC-6-21)-
(9CI) (CA INDEX NAME)




RN 865834-19-1 HCPLUS

CN Sulfur, [3,5-dichloro-4-[3-cyano-5-[(2-(dimethylamino)ethyl)methylamino]-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1H-pyrazol-1-yl]phenylpentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865834-20-4 HCPLUS

CN Sulfur, [3,5-dichloro-4-[3-cyano-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-5-[(2-(1-piperidinyl)ethyl)methylamino]-1H-pyrazol-1-yl]phenylpentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)



RN 1027267-86-2 HCPLUS
 CN INDEX NAME NOT YET ASSIGNED




IT 865833-21-2P 865833-22-3P 865833-23-4P
 865833-24-5P 865833-25-6P 865833-26-7P
 865833-27-8P 865833-28-9P 865833-29-0P
 865833-30-3P 865833-31-4P 865833-32-5P
 865833-33-6P 865833-34-7P 865833-35-8P
 865833-36-9P 865833-37-0P 865833-38-1P
 865833-39-2P 865833-40-5P 865833-41-6P
 865833-42-7P 865833-44-9P 865833-45-0P
 865833-57-4P 865833-58-5P 865833-59-6P
 865833-60-9P 865833-61-0P 865833-62-1P
 865833-64-3P 865833-65-4P 865833-66-5P
 865833-67-6P 865833-68-7P 865833-69-8P
 865833-70-1P 865833-93-8P 865833-94-9P
 865833-95-0P 1034344-02-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-(1-arylpyrazol-4-yl) sulfonamides as parasiticides)


RN 865833-21-2 HCPLUS

CN Methanimidamide, N'-[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[[3,4-difluorophenyl]sulfonyl]amino]-1H-pyrazol-5-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 865833-22-3 HCPLUS

CN Methanimidamide, N'-(3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(methylsulfonyl)methylsulfonyl]amino)-1H-pyrazol-5-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 865833-23-4 HCPLUS

CN Sulfur, [3,5-dichloro-4-[3-cyano-5-[(dimethylamino)methylene]amino]-4-[(methylsulfonyl)amino]-1H-pyrazol-1-yl]phenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)



RN 865833-24-5 HCPLUS


CN Methanimidamide, N'-(3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(phenylmethyl)sulfonyl]amino)-1H-pyrazol-5-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 865833-25-6 HCPLUS

CN Methanimidamide, N'-(3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(1E)-2-phenylethensulfonyl]amino)-1H-pyrazol-5-yl)-N,N-dimethyl-
(CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 865833-26-7 HCPLUS


CN Methanimidamide, N'-(3-cyano-4-[(cyclopropylmethyl)(methylsulfonyl)amino]-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl)-N,N-dimethyl-
(CA INDEX NAME)

RN 865833-27-8 HCPLUS


CN Methanimidamide, N'-(3-cyano-4-[(cyanomethyl)(methylsulfonyl)amino]-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl)-N,N-dimethyl-
(CA INDEX NAME)




RN 865833-28-9 HCAPLUS
 CN Methanimidamide, N'-(3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(methylsulfonyl)(2-pyridinylmethyl)amino]-1H-pyrazol-5-yl)-N,N-dimethyl-
 (CA INDEX NAME)



RN 865833-29-0 HCAPLUS
 CN Methanimidamide, N'-(3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(methylsulfonyl)(phenylmethyl)amino]-1H-pyrazol-5-yl)-N,N-dimethyl-
 (CA INDEX NAME)




RN 865833-30-3 HCAPLUS
 CN Methanimidamide, N'-(3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(2-hydroxyethyl)(methylsulfonyl)amino]-1H-pyrazol-5-yl)-N,N-dimethyl-
 (CA INDEX NAME)




RN 865833-31-4 HCPLUS

CN Methanimidamide, N'-(3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(methylsulfonyl)[(methylthio)methyl]amino]-1H-pyrazol-5-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 865833-32-5 HCPLUS

CN Methanimidamide, N'-(3-cyano-4-[cyclobutyl[(trifluoromethyl)sulfonyl]amino]-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 865833-33-6 HCPLUS


CN Methanimidamide, N'-(3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(2-(dimethylamino)ethyl)(methylsulfonyl)amino]-1H-pyrazol-5-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 865833-34-7 HCPLUS
CN Sulfur, [3,5-dichloro-4-[3-cyano-5-[(dimethylamino)methylene]amino]-4- [methyl[(trifluoromethyl)sulfonyl]amino]-1H-pyrazol-1- yl]phenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)



RN 865833-35-8 HCPLUS
CN Methanimidamide, N'-(3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-(methylsulfonyl)amino)-1H-pyrazol-5-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 865833-36-9 HCPLUS
CN Methanimidamide, N'-[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfonyl]amino]-1H-pyrazol-5-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 865833-37-0 HCAPLUS

CN Methanimidamide, N'-(3-cyano-4-[(cyclopropylsulfonyl)(methylsulfonyl)amino]-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 865833-38-1 HCAPLUS

CN Methanimidamide, N'-(3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(dimethylamino)sulfonyl](methylsulfonyl)amino)-1H-pyrazol-5-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 865833-39-2 HCAPLUS

CN Methanimidamide, N'-(4-[bis(methylsulfonyl)amino]-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 865833-40-5 HCPLUS

CN Sulfur, [4-[4-[bis(methylsulfonyl)amino]-5-[(dimethylamino)methylene]amino]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-41-6 HCPLUS

CN Methanimidamide, N'-(4-[bis(methylsulfonyl)amino]-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)thio]phenyl)-1H-pyrazol-5-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 865833-42-7 HCPLUS

CN Methanimidamide, N'-(4-[bis(methylsulfonyl)amino]-3-cyano-1-[2,6-dichloro-4-(difluoromethoxy)phenyl]-1H-pyrazol-5-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 865833-44-9 HCPLUS

CN Sulfur, [3,5-dichloro-4-[3-cyano-5-[(dimethylamino)methylene]amino]-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1H-pyrazol-1-yl]phenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-45-0 HCPLUS

CN Sulfur, [3,5-dichloro-4-[3-cyano-5-[(dimethylamino)methylene]amino]-4-[(methylsulfonyl)[1-(trifluoromethyl)cyclopropyl]methylamino]-1H-pyrazol-1-yl]phenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-57-4 HCPLUS

CN Sulfur, [4-[3-(aminocarbonyl)-4-[bis(methylsulfonyl)amino]-5-[(dimethylamino)methylene]amino]-1H-pyrazol-1-yl]-3,5-dichlorophenylpentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-58-5 HCPLUS

CN Sulfur, [4-[3-acetyl-4-[bis(methylsulfonyl)amino]-5-[(dimethylamino)methylene]amino]-1H-pyrazol-1-yl]-3,5-dichlorophenylpentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-59-6 HCPLUS


CN Methanesulfonamide, N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 865833-60-9 HCPLUS
 CN Sulfur, [3,5-dichloro-4-[3-cyano-5-[(2-(dimethylamino)ethyl)methylamino]-4-[(methylsulfonyl)amino]-1H-pyrazol-1-yl]phenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)



RN 865833-61-0 HCPLUS
 CN Sulfur, [3,5-dichloro-4-[3-cyano-4-[(methylsulfonyl)amino]-5-[(2-(1-piperidinyl)ethyl)methylamino]-1H-pyrazol-1-yl]phenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-62-1 HCPLUS
 CN Sulfur, [3,5-dichloro-4-[3-cyano-5-[(dimethylamino)methylene]amino]-4-[(methylsulfonyl)[2-(1H-1,2,4-triazol-1-yl)ethyl]amino]-1H-pyrazol-1-yl]phenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-64-3 HCPLUS

CN Sulfur, [4-[4-[bis(methylsulfonyl)amino]-3-cyano-5-[(phenylmethylene)amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-65-4 HCPLUS

CN Sulfur, [3,5-dichloro-4-[3-cyano-5-[(dimethylamino)methylene]amino]-4-[(trifluoromethyl)sulfonyl]amino]-1H-pyrazol-1-yl]phenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-66-5 HCPLUS

CN Methanimidamide, N'-[4-[bis[(trifluoromethyl)sulfonyl]amino]-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 865833-67-6 HCPLUS

CN Sulfur, [3,5-dichloro-4-[3-cyano-5-iodo-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1H-pyrazol-1-yl]phenyl]pentafluoro-, (OC-6-21)-(9CI) (CA INDEX NAME)



RN 865833-68-7 HCPLUS


CN Sulfur, [3,5-dichloro-4-[3-cyano-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-5-[(2-oxoethyl)amino]-1H-pyrazol-1-yl]phenyl]pentafluoro-, (OC-6-21)-(9CI) (CA INDEX NAME)



RN 865833-69-8 HCPLUS


CN Methanimidamide, N'-[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-

[methyl[(trifluoromethyl)sulfonyl]amino]-1H-pyrazol-5-yl]-N,N-dimethyl-
(CA INDEX NAME)




RN 865833-70-1 HCPLUS

CN Methanimidamide, N'-[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-(1,1-dioxido-2-isothiazolidinyl)-1H-pyrazol-5-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 865833-93-8 HCPLUS

CN Sulfur, [4-[4-[(2-bromoethyl)(methylsulfonyl)amino]-3-cyano-5-[(dimethylamino)methylene]amino]-1H-pyrazol-1-yl]-3,5-dichlorophenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-94-9 HCPLUS

CN Sulfur, [3,5-dichloro-4-[3-cyano-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-5-(2-propenylamino)-1H-pyrazol-1-yl]phenyl]pentafluoro-, (OC-6-21)- (9CI) (CA INDEX NAME)




RN 865833-95-0 HCPLUS

CN Methanimidamide, N'-[4-[(3-chloropropyl)sulfonyl]amino]-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 1034344-02-9 HCPLUS

CN Methanimidamide, N'-[3-cyano-4-[(cyclopropylmethyl)[(trifluoromethyl)sulfonyl]amino]-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-N,N-dimethyl- (CA INDEX NAME)



REFERENCE COUNT:

18

THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Structure Search

=> FILE HCPLUS
FILE 'HCPLUS' ENTERED AT 13:34:07 ON 16 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Apr 2009 VOL 150 ISS 16
FILE LAST UPDATED: 15 Apr 2009 (20090415/ED)

HCplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.


CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCPLUS' FILE

=> D STAT QUE L27
L9 STR



Structure attributes must be viewed using STN Express query preparation.
L12 2562 SEA FILE=REGISTRY SSS FUL L9

L14

STR



Structure attributes must be viewed using STN Express query preparation.
 L17 263 SEA FILE=REGISTRY SUB=L12 SSS FUL L14
 L18 42 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L17
 L19 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
 L21 2 SEA FILE=REGISTRY SUB=L12 SSS FUL L19
 L22 1 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L21
 L27 42 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON (L18 OR L22) AND
 (PRY<=2006 OR PY<=2006 OR AY<=2006)

=> S L27 NOT L26
 L39 41 L27 NOT L26

=> FILE WPIX
 FILE 'WPIX' ENTERED AT 13:34:27 ON 16 APR 2009
 COPYRIGHT (C) 2009 THOMSON REUTERS

FILE LAST UPDATED: 9 APR 2009 <20090409/UP>
 MOST RECENT UPDATE: 200923 <200923/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
 >>> Now containing more than 1.3 million chemical structures in DCR <<

>>> IPC and US National Classifications have been updated
 with reclassifications to the end of 2008.
 ECLA, F-Term and FI-Term classifications are complete
 to the end of 2008.
 No update date (UP) has been created for the reclassified
 documents, but they can be identified by
 specific update codes (see HELP CLA for details)<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
 PLEASE VISIT:
http://www.stn-international.com/stn_guide.html

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/>

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/DWPINaVist2_0608.html

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

'BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> D STAT QUE L30
L19 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L29 2 SEA FILE=WPIX SSS FUL L19
L30 1 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L29/DCR

=> S L30 NOT L31
L40 0 L30 NOT L31

=> FILE MARPAT
FILE 'MARPAT' ENTERED AT 13:34:45 ON 16 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 150 ISS 15 (20090410/ED)

MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 20090068566 12 MAR 2009
DE 102008006717 19 FEB 2009
EP 2025678 18 FEB 2009
JP 2009043980 26 FEB 2009
WO 2009030098 12 MAR 2009
GB 2451715 11 FEB 2009
FR 2920023 20 FEB 2009
RU 2347785 27 FEB 2009
CA 2597193 13 FEB 2009

The new MARPAT User Guide is now available at:
<http://www.cas.org/support/stngen/stndoc/marpat.html>.

=> D STAT QUE L37
L35 STR

Structure attributes must be viewed using STN Express query preparation:
Uploading strl35.str
L37 3 SEA FILE=MARPAT SSS FUL L35

100.0% PROCESSED 2286 ITERATIONS
SEARCH TIME: 00.00.04

3 ANSWERS

=> DUP REM L39 L40 L37
 L40 HAS NO ANSWERS
 FILE 'HCAPLUS' ENTERED AT 13:34:58 ON 16 APR 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MARPAT' ENTERED AT 13:34:58 ON 16 APR 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)
 PROCESSING COMPLETED FOR L39
 PROCESSING COMPLETED FOR L40
 PROCESSING COMPLETED FOR L37
 L41 43 DUP REM L39 L40 L37 (1 DUPLICATE REMOVED)
 ANSWERS '1-40' FROM FILE HCAPLUS
 ANSWERS '41-43' FROM FILE MARPAT

=> D IBIB ED ABS HITSTR 1-40; D IBIB AB HITSTR 41-43

L41 ANSWER 1 OF 43 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 1
 ACCESSION NUMBER: 1969:87657 HCAPLUS Full-text
 DOCUMENT NUMBER: 70:87657
 ORIGINAL REFERENCE NO.: 70:16377a,16380a
 TITLE: Synthesis and pharmacological properties of pyrazole derivatives. I. 1-Phenyl-4-aminopyrazole derivatives
 AUTHOR(S): Fusco, Raffaello; Bianchi, M.; Bonacina, F.; Osvaldo, A.
 CORPORATE SOURCE: Lab. Ric. "Vister", Casatenovo Brianza, Como, Italy
 SOURCE: Farmaco, Edizione Scientifica (1968),
 23(10), 919-44
 CODEN: FRPSAX; ISSN: 0430-0920
 DOCUMENT TYPE: Journal
 LANGUAGE: Italian
 ED Entered STN: 12 May 1984
 AB 1-Phenyl-3-(R-substituted) 5-(R1-substituted)-4-(R2R3N-substituted)- pyrazoles (I), 1-phenyl-3 - (R - substituted)-4-(R1-substituted) - 5 - (R2- substituted)-pyrazoles (II), N, N, N-trimethyl-N-[1-phenyl-3-(R-substituted)- 5-(R1-substituted)-pyrazol-4- yl]ammonium salts (anion designated X) (III), and 4-(R-substituted)-5-(R1-substituted)-1-phenyl-3-methylpyrazolium salts (anion designated X) (IV) are prepared according to known methods and tested for antipyretic activity in rats, analgesic activity in rats and mice, and antiinflammatory activity in rats. Thus, 1 mole of a 4-aminopyrazole is treated with 1.1 moles p-MeC6H4SO2Cl to give the following I (R2 = H, R3 = p-MeC6H4SO2) (R, R1, and m.p. given): H, H, 180-2°; Me, H, 159-60°; Me, Me, 185-6°; these are treated with Me2SO4 and Et2SO4 to give the following I (R3 = p-MeC6H4SO2) (R, R1, R2, and m.p. given): H, H, Me, 81-3°; Me, H, Me, 104-5°; Me, Me, Me, 115-17°; H, H, Et, 137-9°; Me, H, Et, 85-6°; and Me, Me, Et, 67-9°. Also prepared, according to known methods, are the following I (R, R1, R2, R3, b.p./mm., m.p., and m.p. HCl salt given): H, H, H, H, -, 105-7°, -; Me, Me, H, H, -, -, (monohydrate m. 64-7°); H, H, H, Me, -, 49-51°, 175-6°; Me, H, H, Me, 122-5°/0.1, -, 149-50°; Me, Me, H, Me, 130°/0.05, -, 228-30°; H, H, H, Et, 125-7°/0.1, -, 223-5°; Me, H, H, Et, 125-30°/0.1, -, 168-70°; Me, Me, H, Et, 130°/0.05, -, 177-9°; H, H, H, iso-Pr, 120°/0.1, -, 188-90°; H, H, H, sec-amyl, 135-8°/0.2, -, 152-4°; H, H, H, cyclopentyl, 130-5°/0.1, -, 190-2°; H, H, H, cyclohexyl, 153-6°/0.1, 65-7°, 259-61°; H, H, H, cycloheptyl, 155-62°/0.1, 58-60°, 196-8°; H, H, H, allyl, -, -, 180-2° (picrate m. 146-8°);

H, H, H, CH₂SO₃Na, -, -, - [Na salt monohydrate m. 260° (decomposition)]; H, H, Me, Me, 120-1°/0.05, 45-6°, 169-71° (HBr salt m. 186-7°; picrate m. 172-3°; oxalate m. 145-7°); Me, H, Me, Me, 115-20°/ 0.2, -, 188-90° [HBr salt m. 205-7° (decomposition)]; H, Me, Me, Me, 102-3°/0.1, 67-9°, 193-5° (HBr salt m. 173-5°); Me, Me, Me, 107°/0.1, 40-1°, 183-5° (picrate m. 120-2°); H, H, Me, Et, 118-22°/0.1, -, 164-5°; H, H, Me, iso-Pr, 115-17°/ 0.1, -, 172-4°; H, H, Et, Et, 122-4°/0.1, -, 168-9°; H, H, allyl, allyl, 130-2°/0.1, -, 116-18° (picrate m. 143-5°); H, allyl, allyl, allyl, 129-31°/0.1, -, 140-2°; H, Br, Me, Me, -, -, - (HBr salt m. 134-5°); Me, Br, Me, Me, 85°/0.05, -, - (HBr salt m. 170-1° (decomposition)]; H, Cl, Me, Me, 107°/0.1, 55-6°, 154-5°; Me, Cl, Me, Me, 100-2°/0.1, -, 195-7° (decomposition); H, F, Me, Me, 85°/0.05, -, 135-7° (picrate m. 151-3°); H, p-O₂NC₆H₄N: N, Me, Me, -, 141-3°, -; H, NO₂, Me, Me, -, 110-12°, -; Me, NO₂, Me, Me, -, 123-5°, -; H, NH₂, Me, Me, -, 117-19°, 180-1°; H, AcNH, Me, Me, -, -, 197-9° [picrate m. 125-8° (decomposition)]; H, Ac₂N, Me, Me, 136-9°/0.1, 95-7°, 164-6° (picrate m. 158-60°); H, HOCH₂, Me, Me, -, 108-10°, - [picrate m. 125-7° (decomposition)]; H, BzOCH₂, Me, Me, -, -, 122-4°; H, H, H, Ac, -, 123-5°, -; H, H, H, p-H₂NC₆H₄CO, -, 176-8°, -; H, Ph, H, H, 170-1°/ 0.1, 129-31°, 270° (decomposition); and H, Ph, Me, Me, -, 110-12° (sublimes at 125° at 0.1 mm.), 198-200° (decomposition). Also prepared was bis(1-phenyl-4-dimethylaminopyrazol-5- yl)methane, m. 182-3°; dipicrate m. 184-5°; dimethiodide m. 214-16° (decomposition). Also prepared were the following II (R, R₁, R₂, b.p./mm., m.p., and salt m.p. given): H, H, H, 244-6°/730, -, -, -; H, iso-Pr, H, 87-90°/0.1, -, -, CO₂H, iso-Pr, H, -, -, - (monohydrate m. 88-90°); NH₂, H, H, -, 94-5°, -; Me₂N, H, H, 95-7°/0.1, -, HCl 175-7°; H, H, NH₂, 115-18°/ 0.1, 44-6°, -; and H, H, Me₂N, 160-1°/15, -, HCl 134-5°. Also prepared were the following III (R, R₁ X, m.p., and salt m.p. given): H, H, MeSO₄, -, -, (monohydrate m. 95-10°; hemihydrate m. 141-3°); H, H, picrate, 164-6°, -; H, H, OH, 195° (decomposition), -; H, H, Br, 229-31° (decomposition), -; Me, H, MeSO₄, 155-7°, -; Me, H, Br, 222-4°, -; H, Me, MeSO₄, 205-7°, -; and H, Me, Br, 215-16° (decomposition), -. Also prepared were the following IV (R, R₁, X, b.p./mm., and m.p. given): H, H, iodine, -, 180-1° (decomposition); iso-Pr, H, iodine, -, 124-6°; H, NH₂, Cl, 100-5°/0.1, 237-9° (decomposition); and H, Me₂N, iodine, -, 169-70°. 1-Phenyl-4-dimethylaminopyrazole has antipyretic and antiinflammatory properties similar to those of Pyramidon.

IT 17551-11-0P 21274-85-1P 21274-86-2P


21274-87-3P 21274-88-4P 21274-89-5P

21274-90-8P 21274-91-9P 21274-92-0P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 17551-11-0 HCPLUS


CN Benzenesulfonamide, 4-methyl-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX
NAME)




RN 21274-85-1 HCAPLUS
CN Benzenesulfonamide, 4-methyl-N-(3-methyl-1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)



RN 21274-86-2 HCAPLUS
CN Benzenesulfonamide, N-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-4-methyl- (CA INDEX NAME)




RN 21274-87-3 HCAPLUS
CN Benzenesulfonamide, N,4-dimethyl-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)




RN 21274-88-4 HCPLUS

CN Benzenesulfonamide, N,4-dimethyl-N-(3-methyl-1-phenyl-1H-pyrazol-4-yl)-
(CA INDEX NAME)




RN 21274-89-5 HCPLUS

CN Benzenesulfonamide, N-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-N,4-dimethyl-
(CA INDEX NAME)




RN 21274-90-8 HCPLUS

CN Benzenesulfonamide, N-ethyl-4-methyl-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)




RN 21274-91-9 HCPLUS

CN Benzenesulfonamide, N-ethyl-4-methyl-N-(3-methyl-1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)



RN 21274-92-0 HCPLUS



CN Benzenesulfonamide, N-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-N-ethyl-4-methyl- (CA INDEX NAME)



L41 ANSWER 2 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:430797 HCPLUS Full-text
 DOCUMENT NUMBER: 141:7108
 TITLE: Preparation of pyrazoles as modulators of peroxisome
 proliferator activated receptors (PPARs), in
 particular PPAR γ agonists
 INVENTOR(S): Huck, Jacques; Saladin, Regis; Sierra, Michael
 CAREX SA, Fr.
 PATENT ASSIGNEE(S): PCT Int. Appl., 156 pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043951	A1	20040527	WO 2003-EP11855	20031024 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003282051	A1	20040603	AU 2003-282051	20031024 <--
PRIORITY APPLN. INFO.:			EP 2002-360298	A 20021024 <--
			EP 2002-360372	A 20021220 <--
			EP 2002-360373	A 20021220 <--
			US 2003-456954P	P 20030325 <--
			EP 2003-360070	A 20030611 <--
			EP 2003-360091	A 20030724 <--
			WO 2003-EP11855	W 20031024 <--


OTHER SOURCE(S): MARPAT 141:7108
 ED Entered STN: 27 May 2004
 GI




AB Title compds. I [wherein R1 = H, CF₃, (un)substituted alkyl, cycloalkyl, heterocyclyl, etc.; R2 = (un)substituted alkyl, amino, COH, etc.; n = 0-6; R11 and R12 = independently H, alkyl, CO₂H and derivs., OH and derivs., NH₂ and derivs., etc.; their analogs, derivs., solvates or salts] were prepared for modulating peroxisome proliferator activated receptors (PPARs), in particular as PPAR_γ agonists, and for treating and/or preventing various diseases and conditions mediated by said nuclear receptors, including metabolic or cell proliferative disorders (no data). For example, 1-phenyl-3-(thiophen-2-yl)-1H-pyrazole-4-carboxaldehyde (preparation given) was reacted with 1-(4-methoxyphenyl)ethanone in isopropanol to give II in 67% yield. II inhibited adipocyte differentiation induced by rosiglitazone by about 68%, demonstrating its antagonistic activity towards human PPAR_γ. II induced adipocyte differentiation (25% of rosiglitazone efficacy), proving its human PPAR_γ partial agonistic activity. I are useful for treating diabetes, atherosclerosis, hyperglycemia, dyslipidemia, obesity, syndrome X, insulin resistance, hypertension, neuropathy, microvascular diseases (e.g. retinopathy, nephropathy), macrovascular diseases (e.g. myocardial infarction, stroke, heart failure) in mammals.(no data).

IT 694435-85-3P, 4-Methoxy-N-[1-phenyl-3-(thiophen-2-yl)-1H-pyrazol-4-yl]benzenesulfonamide 694435-86-4P,
 4-Methoxy-N-methyl-N-[1-phenyl-3-(thiophen-2-yl)-1H-pyrazol-4-yl]benzenesulfonamide 694435-88-6P,
 1-Phenyl-N-[1-phenyl-3-(thiophen-2-yl)-1H-pyrazol-4-yl]methanesulfonamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (PPAR_γ agonist; preparation of pyrazoles as modulators of peroxisome proliferator activated receptors (PPARs), in particular PPAR_γ agonists)


RN 694435-85-3 HCPLUS
 CN Benzenesulfonamide, 4-methoxy-N-[1-phenyl-3-(2-thienyl)-1H-pyrazol-4-yl]-(CA INDEX NAME)



RN 694435-86-4 HCPLUS
 CN Benzenesulfonamide, 4-methoxy-N-methyl-N-[1-phenyl-3-(2-thienyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)



RN 694435-88-6 HCPLUS
 CN Benzenemethanesulfonamide, N-[1-phenyl-3-(2-thienyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 3 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:356201 HCPLUS [Full-text](#)
 DOCUMENT NUMBER: 138:368888
 TITLE: Pyrazolecarboxamides and -sulfonamides as sodium channel blockers
 INVENTOR(S): Atkinson, Robert Nelson; Gross, Michael Francis
 PATENT ASSIGNEE(S): Icagen, Inc., USA
 SOURCE: PCT Int. Appl., 132 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037274	A2	20030508	WO 2002-US35172	20021101 <--
WO 2003037274	A3	20031030		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2465207	A1	20030508	CA 2002-2465207	20021101 <--
AU 2002363250	A1	20030512	AU 2002-363250	20021101 <--
EP 1451160	A2	20040901	EP 2002-799175	20021101 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 20050049237	A1	20050303	US 2002-286304	20021101 <--
US 7223782	B2	20070529		
US 20080064690	A1	20080313	US 2007-740845 US 2001-335958P US 2002-286304 WO 2002-US35172	20070426 <-- P 20011101 <-- A1 20021101 <-- W 20021101 <--
PRIORITY APPLN. INFO.:				

OTHER SOURCE(S): MARPAT 138:368888

ED Entered STN: 09 May 2003

GI



AB Pyrazolecarboxamides and -sulfonamides were prepared for use in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels, especially pain and chronic pain. Thus, the amide I was prepared by amidation of the acid chloride with the amine and showed activity at the PNS Na channel in the 4.1-10 μ M range.


IT 521929-45-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolecarboxamides and -sulfonamides as sodium channel blockers)

RN 521929-45-3 HCPLUS

CN Sulfamide, N-[1-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]-N'-

PAGE 1-A




PAGE 2-A

II

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L41 ANSWER 4 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:552374 HCPLUS [Full-text](#)
 DOCUMENT NUMBER: 137:78950
 TITLE: Preparation of functionalized bipyrrazoles as nonsteroidal antiinflammatory agents
 INVENTOR(S): Barreiro, Eliezer Jesus de Lacerda; Fraga, Carlos Alberto Manssour; Palhares de Miranda, Ana Luisa; Rodrigues, Carlos Rangel; Veloso, Marcia Paranhos
 PATENT ASSIGNEE(S): Brazil
 SOURCE: Braz. Pedido PI, 33 pp.
 CODEN: BPXXDX
 DOCUMENT TYPE: Patent
 LANGUAGE: Portuguese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BR 9902960	A	20010821	BR 1999-2960	19990429 <--
PRIORITY APPLN. INFO.:			BR 1999-2960	19990429 <--
OTHER SOURCE(S):	MARPAT	137:78950		
ED Entered STN:	26 Jul 2002			
GI				




I


AB Bipyrazoles I [R, R1 = H, alkyl, (un)substituted phenyl; R2 = H, alkyl; R3 = alkyl, NO₂, MeO, Cl, F, Br] were prepared for use as nonsteroidal antiinflammatory agents. Thus, 4'-(methanesulfonylamino)-3'-methyl-1'-phenyl-1,5'-bipyrazole was prepared from 3'-methyl-4'-nitro-1'-phenyl-1,5'-bipyrazole by nitro group reduction (Fe/NH₄Cl, NaBH₄/Na₂SO₄, or NaBH₄/SnCl₂) and methanesulfonylation using mesyl chloride and pyridine in CH₂Cl₂.
 IT 440367-26-0P 440367-27-1P 440367-28-2P
 440367-29-3P 440367-30-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of functionalized bipyrazoles as nonsteroidal antiinflammatory agents)
 RN 440367-26-0 HCPLUS
 CN Methanesulfonamide, N-(3'-methyl-1'-phenyl[1,5'-bi-1H-pyrazol]-4'-yl)- (9CI) (CA INDEX NAME)




RN 440367-27-1 HCPLUS
 CN Methanesulfonamide, N-(3,3',5-trimethyl-1'-phenyl[1,5'-bi-1H-pyrazol]-4'-yl)- (9CI) (CA INDEX NAME)




RN 440367-28-2 HCAPLUS
 CN Methanesulfonamide, N-(3'-methyl-1',3,5-triphenyl[1,5'-bi-1H-pyrazol]-4'-yl)- (9CI) (CA INDEX NAME)



RN 440367-29-3 HCAPLUS
 CN Methanesulfonamide, N-(3',5-dimethyl-1'-phenyl[1,5'-bi-1H-pyrazol]-4'-yl)- (9CI) (CA INDEX NAME)



RN 440367-30-6 HCAPLUS
 CN Methanesulfonamide, N-(3',5-dimethyl-1',3-diphenyl[1,5'-bi-1H-pyrazol]-4'-yl)- (9CI) (CA INDEX NAME)



L41 ANSWER 5 OF 43 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2000:235253 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 133:4619
 TITLE: Reaction of N-acyl and N-arylsulfonyl derivatives of
 2-amino-3,3-dichloroacrylonitrile with phenylhydrazine
 Brovarets, V. S.; Pill'o, S. G.; Chernega, A. N.;
 Romanenko, E. A.; Drach, B. S.

CORPORATE SOURCE: Institute of Bioorganic and Petroleum Chemistry,
Ukrainian National Academy of Sciences, Kiev, Ukraine

SOURCE: Russian Journal of General Chemistry (Translation of
Zhurnal Obshchei Khimii) (1999), 69(10),
1577-1582

CODEN: RJGCEK; ISSN: 1070-3632

PUBLISHER: MAIK Nauka/Interperiodica Publishing

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 12 Apr 2000


AB Cyclization of N-acyl and N-alkoxycarbonyl derivs. of 2-amino-3,3-dichloroacrylonitrile with phenylhydrazine lead to formation of new functionally substituted oxazoles and pyrazoles, resp. By contrast, 2-arylsulfonylamino-3,3-dichloroacrylonitriles or, most probably, the corresponding arylsulfonylimino tautomers with phenylhydrazine form only open-chain products via replacement of the cyano group and two chlorine atoms by PhNNH- and PhNN: residues. Structurally related 2-[arylsulfonyl(methyl)amino]-3,3-dichloroacrylonitriles $C_12C:C(CN)N(CH_3)SO_2Ar$, which are incapable of tautomeric transformation, react with phenylhydrazine to give cyclocondensation products through participation of the two chlorine atoms and the cyano group; subsequent oxidation yields 5-amino-4-[arylsulfonyl(methyl)amino]-3-phenylazopyrazoles. The structure of one of these products was proved by single crystal X-ray diffraction.

IT 270569-99-8P 270570-00-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(reaction of N-acyl and N-arylsulfonyl derivs. of
aminodichloroacrylonitrile with phenylhydrazine)


RN 270569-99-8 HCPLUS

CN Benzenesulfonamide, N-[5-amino-1-phenyl-3-(2-phenyldiazenyl)-1H-pyrazol-4-yl]-N-methyl- (CA INDEX NAME)




RN 270570-00-8 HCPLUS

CN Benzenesulfonamide, N-[5-amino-1-phenyl-3-(2-phenyldiazenyl)-1H-pyrazol-4-yl]-N,4-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 6 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1997:196854 HCPLUS Full-text
 DOCUMENT NUMBER: 126:264074
 ORIGINAL REFERENCE NO.: 126:51149a,51152a
 TITLE: Synthesis and biological screening of N4-phthalimidomethyl sulfonamides
 AUTHOR(S): Joshi, Sheela; Matkar, Satish; Khosla, Navita;
 Bhandari, Vinita
 CORPORATE SOURCE: Inst. Chem. Sci., Indore, 452 001, India
 SOURCE: Journal of the Indian Chemical Society (1997
), 74(2), 156-157
 CODEN: JICSAH; ISSN: 0019-4522
 PUBLISHER: Indian Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 126:264074
 ED Entered STN: 26 Mar 1997
 GI



I

AB Phthalimidomethyl sulfonamides I (R = H, 2-pyrimidinyl, etc.) were prepared by reacting phthalimide with 4-H2NC6H4SO2NHR. I were screened for antibacterial activity.


IT 188791-04-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antibacterial activity of N-phthalimidomethyl sulfonamides)

RN 188791-04-0 HCPLUS

CN Benzenesulfonamide, 4-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]amino]-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)




IT 15520-50-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and antibacterial activity of N-phthalimidomethyl sulfonamides)

RN 15520-50-0 HCPLUS

CN Benzenesulfonamide, 4-amino-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 7 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:129531 HCPLUS [Full-text](#)

DOCUMENT NUMBER: 126:137635

ORIGINAL REFERENCE NO.: 126:26487a,26490a

TITLE: High contrast silver halide photographic material containing a development-inhibitor precursor and the imaging method by using the material

INVENTOR(S): Miura, Akio; Komamura, Tawara

PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 23 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08314055	A	19961129	JP 1995-122551	19950522 <--

PRIORITY APPLN. INFO.:

JP 1995-122551

19950522 <--

ED Entered STN: 26 Feb 1997


AB Claimed photog. material comprising a support and a silver halide emulsion layer containing grains with the average diameter of $\leq 0.3\mu\text{m}$ and AgCl content of ≥ 60 mol.% contains a development inhibitor precursor $\text{GQ:S(T;U)m-1(V;W)n-1NHSO2PUG}$ (I ; $\text{m, n} = 0, 1$; $\text{Q} = \text{N, CR1:; S} = \text{N, CR2:; T} = \text{N, CR3:; U} = \text{N, CR4:; V} = \text{N, CR5:; W} = \text{N, CR6:; R1-R6} = \text{H}$, monovalent organic group; $\text{G} = \text{OR7, NR8R9; R7} = \text{H}$, dissociable group; $\text{R8, R9} = \text{H}$, SO3PUG , monovalent organic group; G and W may be combined to form a single carbon ring, condensed ring or heterocyclic ring; PUG = development inhibiting moiety). It preferably incorporate a hydrazine derivative. Also claimed is the method for development of the material using a developer with the pH of ≤ 11.0 . The material provides an image with high contrast and long dot gradation suitable for photomech. processes, and the developer provides a good process consistency. Examples of the compound I includes 2-hexadecylcarbamoyl-3-PUG-sulfoamino-4,5-(4-methoxybenzo)pyrrole, 3-hexadecylsulfo-ethyl-6-methyl-7-PUG-sulfoamino-terazaindene, 1-trichlorophenyl-3-pentadecyl-4-PUG-sulfoaminopyrazolone, etc. where PUG is 6-nitrobenzimidazole-1-yl, 6-nitrobenzotriazole-1-yl, 1,2-bis-(1,2,4-triazol-3-yl)hydrazine, etc.

IT 186463-49-0

RL: DEV (Device component use); USES (Uses)
(high-contrast photog. material containing development-inhibitor precursor and imaging formation)

RN 186463-49-0 HCPLUS

CN 1H-Benzimidazole-1-sulfonamide, N-[5-amino-3-pentadecyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl]-4-nitro- (CA INDEX NAME)



L41 ANSWER 8 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:559603 HCPLUS [Full-text](#)

DOCUMENT NUMBER: 123:143711

ORIGINAL REFERENCE NO.: 123:25601a,25604a

TITLE: Thiazolidinones: some new 4-thiazolidinones for antitubercular activity

AUTHOR(S): Solankee, Anjani; Kapadia, Kishor

CORPORATE SOURCE: Chemistry Department, B. K. M. Science College, Valsad, 396 001, India

SOURCE: Journal of the Institution of Chemists (India) (1994), 66(3), 87-8

CODEN: JOICAA7; ISSN: 0020-3254

PUBLISHER: Institution of Chemists (India)



DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 123:143711

ED Entered STN: 18 May 1995

GI



AB 4-Thiazolidinones I (R = substituted Ph, naphthyl) and II (R1 = Ph, substituted Ph, R2 = heterocyclyl) were prepared by refluxing Schiff bases, from N-substituted sulfonamides/aryl amines and aryl aldehydes, with 2-mercaptopsebacic acid using benzene as solvent.


IT 166330-90-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of new thiazolidinones with antitubercular activity)

RN 166330-90-1 HCPLUS

CN 5-Thiazolidineoctanoic acid, 2-[4-(dimethylamino)phenyl]-4-oxo-3-[4-[(1-phenyl-1H-pyrazol-4-yl)amino]sulfonyl]phenyl- (CA INDEX NAME)



IT 166330-94-5 166330-95-6


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of new thiazolidinones with antitubercular activity)

RN 166330-94-5 HCPLUS

CN Benzenesulfonamide, 4-[(4-methylphenyl)methylene]amino]-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 166330-95-6 HCPLUS
CN Benzenesulfonamide, 4-[[[4-(dimethylamino)phenyl]methylene]amino]-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



IT 166330-88-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of new thiazolidinones with antitubercular activity)
 RN 166330-88-7 HCPLUS
 CN 5-Thiazolidineoctanoic acid, 2-(4-methylphenyl)-4-oxo-3-[{[(1-phenyl-1H-pyrazol-4-yl)amino]sulfonyl]phenyl}- (CA INDEX NAME)



L41 ANSWER 9 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1994:404900 HCPLUS Full-text
 DOCUMENT NUMBER: 121:1900
 ORIGINAL REFERENCE NO.: 121:1078h,1079a
 TITLE: QSAR and molecular modeling for a series of isomeric
 X-sulfanilamido-1-phenylpyrazoles
 AUTHOR(S): Koch, A.; Seydel, J. K.; Gasco, A.; Tironi, C.;
 Fruttero, R.
 CORPORATE SOURCE: Inst. Comput. Integr. Eng., Univ. Potsdam, Potsdam,
 D-14482, Germany
 SOURCE: Quantitative Structure-Activity Relationships (1993), 12(4), 373-82
 CODEN: QSARDI; ISSN: 0931-8771
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 ED Entered STN: 09 Jul 1994

AB The influence of large substituents in o-, m- and p-positions of the Ph ring of isomeric 3-, 4- and 5-sulfanilamido-1-phenylpyrazoles on their inhibitory effect against *E. coli*-derived dihydropteroic acid synthase and whole cell *E. coli* was studied. According to their pKa values, the 3- and 5-series show high antibacterial activity while the 4-series displays feeble inhibitory activity. In the 3-series the variation in MIC is explained by differences in pKa (Hammett σ) and mol. weight (MW) or substituent surface resp., whereas in the 5-series steric effects of substituents in the o-position of the 1-Ph ring and MW describe the differences in whole cell activity. In the cell-free system the inhibitory activity depends for the 3-series solely on pKa or Hammett σ , resp., and in the 5-series, where the derivs. are almost completely ionized, the variation is solely explainable by the steric effect of the substituents in o-position. The steric effect of o-substituents in the 5-series has been studied and explained by NMR- and mol. modeling techniques. The observed differences in electronic effects of substituents comparing the 3- and 4-series with the 5-series could be explained by the results of quantum chemical calcns.


IT 10476-55-8 15520-50-0 54371-74-3
 54371-75-4 62537-86-4 62537-87-5
 94571-61-6 94571-63-8 94571-65-0
 155667-56-4 155667-57-5 155667-58-6
 155667-59-7 155667-60-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(antibacterial activity of, structure in relation to)


RN 10476-55-8 HCPLUS

CN Benzenesulfonamide, 4-amino-N-(1-(2-chlorophenyl)-1H-pyrazol-4-yl)- (CA INDEX NAME)




RN 15520-50-0 HCPLUS

CN Benzenesulfonamide, 4-amino-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)




RN 54371-74-3 HCPLUS

CN Benzenesulfonamide, 4-amino-N-[1-(4-hydroxyphenyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 54371-75-4 HCPLUS


CN Benzenesulfonamide, 4-amino-N-[1-(2-hydroxyphenyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 62537-86-4 HCPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(2-nitrophenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




RN 62537-87-5 HCPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(3-nitrophenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




RN 94571-61-6 HCAPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(3-methoxyphenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




RN 94571-63-8 HCAPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(2-methoxyphenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




RN 94571-65-0 HCAPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(4-methoxyphenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




RN 155667-56-4 HCAPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(2-methylphenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




RN 155667-57-5 HCPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(2-aminophenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




RN 155667-58-6 HCPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(4-aminophenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)



RN 155667-59-7 HCAPLUS
CN Benzoic acid, 3-{4-[(4-aminophenyl)sulfonyl]amino}-1H-pyrazol-1-yl- (CA
INDEX NAME)




RN 155667-60-0 HCAPLUS
CN Benzoic acid, 4-{4-[(4-aminophenyl)sulfonyl]amino}-1H-pyrazol-1-yl- (CA
INDEX NAME)



L41 ANSWER 10 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1991:618750 HCPLUS Full-text
DOCUMENT NUMBER: 115:218750
ORIGINAL REFERENCE NO.: 115:37141a,37144a
TITLE: Silver halide color photographic materials containing
new couplers
INVENTOR(S): Masukawa, Toyoaki
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03072341	A	19910327	JP 1989-209822	19890814 <--
PRIORITY APPLN. INFO.:			JP 1989-209822	19890814 <--
ED	Entered STN:	15 Nov 1991		
GT				



1


AB Couplers ALnO(LD)X (A = coupler group minus active H; L = bridging group; n = 0, 1; LD = leuco dye group bonded to bridging group or active site of the coupler through O; X = group that separates as X- after liberation) that releases a leuco dye that forms a dye by intramol. electron migration, are contained in the photog. materials. These couplers form 2 mols. of dyes with high efficiency but are themselves colorless and have many uses. Thus, a Ag(I,Br) emulsion was mixed with a dispersion containing a yellow coupler I (10 mol% of Ag) and hardening agent and applied on triacetate film base. Sensitometrically exposed film was normally processed and gave yellow image with d. 2.03. Retention of yellow dye after 20-day storage at 85°, 60% humidity was 95%. The film bleached and fixed without development showed blue absorbance as low as 0.01.

IT 136897-75-1

RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler)

RN 136897-75-1 HCPLUS

CN Benzenesulfonic acid, 1-[5-[1-[(2,5-dichlorophenyl)amino]carbonyl]-3,3-dimethyl-2-oxobutoxy]-3-heptadecyl-1-phenyl-1H-pyrazol-4-yl]-2-(2-methoxyphenyl)hydrazide (CA INDEX NAME)



L41 ANSWER 11 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1991:669965 HCPLUS Full-text

DOCUMENT NUMBER: 115:269965

ORIGINAL REFERENCE NO.: 115:45609a,45612a

TITLE: QSAR and molecular modeling for 3 series of isomeric X-sulfanilamido-1-phenylpyrazoles

AUTHOR(S): Gasco, A.; Koch, A.; Seydel, J. K.

CORPORATE SOURCE: Univ Torino, Turin, I-10125, Italy

SOURCE: Pharmacochemistry Library (1991), 16(QSAR:

Ration. Approaches Des. Bioact. Compd.), 335-8

CODEN: PHLIDQ; ISSN: 0165-7208

DOCUMENT TYPE: Journal


LANGUAGE: English

ED Entered STN: 27 Dec 1991

AB The MIC-values of three series 3-, 4- or 5-sulfanilamido-1-phenylpyrazoles substituted in o-, m- and p-position of the Ph ring have been determined against E. Coli. The differences in inhibitory activities between these series depends on their pKa-values. An addnl. steric influence of the substituents at the Ph ring is assumed and studied by QSAR and mol. mechanics.

IT 15520-50-0D, derivs.


RL: PROC (Process)
 (QSAR and mol. modeling of)
 RN 15520-50-0 HCPLUS
 CN Benzenesulfonamide, 4-amino-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)



L41 ANSWER 12 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1991:91831 HCPLUS [Full-text](#)
 DOCUMENT NUMBER: 114:91831
 ORIGINAL REFERENCE NO.: 114:15497a,15500a
 TITLE: Photographic material containing oxidized developing
 agent-scavenging reducing agent-releasing coupler
 INVENTOR(S): Kida, Shuji; Masukawa, Toyoaki; Ishige, Osamu
 PATENT ASSIGNEE(S): Konica Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 18 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01013547	A	19890118	JP 1987-170305	19870708 <--
JP 07097208	B	19951018	JP 1987-170305	19870708 <--

PRIORITY APPLN. INFO.:
 ED Entered STN: 09 Mar 1991
 GI




AB The title photog. material contains the coupler I [A = a coupler residue releasing group exclusive of A upon reacting with an oxidized developing agent; TIME = a timing group releasing group other than TIME following the coupling reaction; R1 = alkyl, aryl, heterocyclyl; R2 = a substituent; X = OH, NH2OR3, NH2, NHR3, NR3R4; R3, R4 = alkyl, aryl, heterocyclyl; n = 0, 1]. The photog. material shows a good shelflife, possesses superior scavenging capacity for the oxidized developing agent during development, and has good graininess, sharpness, and good sensitivity.

IT 132137-17-8

RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler, oxidized developing agent scavenger-releasing)

RN 132137-17-8 HCAPLUS

CN Pentanamide, 2-[(3,4-bis[(methylsulfonyl)amino]-1-phenyl-1H-pyrazol-5-yl)oxy]-N-[2-chloro-5-[(3-(dodecylsulfonyl)-2-methyl-1-oxopropyl)amino]phenyl]-4,4-dimethyl-3-oxo- (CA INDEX NAME)



L41 ANSWER 13 OF 43 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1989:608691 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 111:208691

ORIGINAL REFERENCE NO.: 111:34423a,34426a

TITLE: Synthesis and biological evaluation of new rhodium(I) complexes with sulfonamide derivatives

AUTHOR(S): Craciunescu, George; Scarcia, Vito; Furlani, Ariella; Parrondo Iglesias, Esther; Ghirvu, Costantin; Papaioannou, Aristotelis

CORPORATE SOURCE: Fac. Pharm., Univ. Madrid, Madrid, 28040, Spain

SOURCE: Anticancer Research (1989), 9(3), 781-5

CODEN: ANTRD4; ISSN: 0250-7005

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 09 Dec 1989


AB New rhodium(I) complexes, belonging to the general structure $[\text{Rh}(\text{CO})_2\text{L}]$, where L were sulfonamide derivs., were synthesized and characterized by chemical anal. and IR detns. These complexes were assayed as cytostatic and antitumor agents in vitro against KB cells and in vivo against P388, Ehrlich ascites, and advanced B16 melanoma. Assays against 3 Trypanosoma strains were also performed. Among the new compds., the $[\text{Rh}(\text{CO})_2(\text{sulfamethoxydiazine})]$ appeared to be active in all biol. systems without showing evident nephrotoxicity. Relationships between biol. activity and π electronic charge localization on N atom of the ligand amidic group are also discussed.

IT 123303-00-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antitumor and trypanosomicidal activity of)


RN 123303-00-4 HCAPLUS

CN Rhodium, [4-amino-N-(1-phenyl-1H-pyrazol-4-



L41 ANSWER 14 OF 43 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1987:449477 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 107:49477
 ORIGINAL REFERENCE NO.: 107:8067a,8070a
 TITLE: Pyrazole-derivatives as color photographic stabilizer
 INVENTOR(S): Ninomiya, Hidetaka
 PATENT ASSIGNEE(S): Konishiroku Photo Industry Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62018557	A	19870127	JP 1985-158931	19850718 <--
JP 05067012	B	19930924		
PRIORITY APPLN. INFO.:			JP 1985-158931	19850718 <--
ED Entered STN: 08 Aug 1987				
GI				




AB A Ag halide color photog. material, resistant to fading or discoloration by light, comprises ≥ 1 color photog. stabilizer I [R = (cyclo)alkyl, alkenyl, aryl, heterocyclic group; X = NH₂, sulfonamide, N-containing heterocyclic group; Y = sulfonamide, acylamino, aniline, sulfamoyl, carbamoyl, ureido, COOH, OH, alcoxycarbonyl, alkyl, alcoxy, aryl, sulfonyl, CN group; Z = H, alkyl, acyl, aryl, heterocyclic group].
 IT 109357-92-8

RL: USES (Uses)

(color photog. stabilizer)

RN 109357-92-8 HCPLUS

CN Benzenesulfonamide, N,N'-(5-ethoxy-1-phenyl-1H-pyrazole-3,4-diyl)bis[4-(dodecyloxy)- (9CI) (CA INDEX NAME)



L41 ANSWER 15 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1986109685 HCPLUS Full-text

DOCUMENT NUMBER: 104:109685

ORIGINAL REFERENCE NO.: 104:17385a,17388a

TITLE: Sulfonylurea derivatives and plant growth regulators or herbicides

INVENTOR(S): Yamamoto, Susumu; Sato, Toshiaki; Igai, Takashi; Oguchi, Toshihiko; Nawamaki, Tsutomu

PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 60214785	A	19851028	JP 1984-59137	19840327 <--
PRIORITY APPLN. INFO.:				JP 1984-59137 19840327 <--
ED Entered STN: 05 Apr 1986				
GI For diagram(s), see printed CA Issue.				
AB (Pyrazolylsulfamoyl)urea derivs. [I, II; R = H, lower alkyl, Ph; R1, R2 = H, lower alkyl, halo, NO2, lower alkoxy, haloalkyl, CO2R3, CONR4R5, SOMeR6, SO2NR7R8, lower alkyl, halo, (NO2-substituted) Ph; R3, R6 = lower alkyl; = H, lower alkyl; R9, R10 = H, lower alkyl, lower alkoxy, lower alkoxyalkyl, halo, NR11R12; Z = NR13, O, CR14R15; R4, R5, R7, R8, R11-R15 = H, lower alkyl; m = 1, 2], useful as plant growth regulators or herbicides, were prepared. Thus, 1.41 g ClSO2NCO was added to 1.55 g 2-amino-4,6-dimethoxypyrimidine in 20 mL THF at 0°, the mixture stirred 1 h at room temperature, a mixture of 1.69 g 4-amino-5-chloro-1,3-dimethylpyrazole, 1.5 g Et3N, and 10 mL THF added at 0°, and the mixture stirred overnight to give 1.2 g I (R = Me; R1 = 3-Me; R2 = 5-Cl; R9 = R10 = OMe; Z = 4-NH), which at 1.25 kg/ha was effective for controlling Cyperus microiria, etc.				
IT 100693-92-3P				

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide and plant growth regulator)
 RN 100693-92-3 HCPLUS
 CN Urea, N-(4,6-dichloro-2-pyrimidinyl)-N'-(methyl(5-methyl-1-phenyl-1H-pyrazol-4-yl)amino)sulfonyl]-(CA INDEX NAME)




L41 ANSWER 16 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1983:143060 HCPLUS Full-text
 DOCUMENT NUMBER: 98:143060
 ORIGINAL REFERENCE NO.: 98:21785a,21788a
 TITLE: Studies in sulfonamides - Part XIII: Synthesis of some new 1-methyl-3-aryl-2-(arylaizo/N-substituted p-sulfamylbenzeneazo)propane-1,3-diones as potential antibacterials
 AUTHOR(S): Nigam, S. C.; Saharia, G. S.; Sharma, H. R.
 CORPORATE SOURCE: Dep. Chem., Univ. Delhi, Delhi, 110 007, India
 SOURCE: Defence Science Journal (1982), 32(2), 87-94
 CODEN: DSJOAA; ISSN: 0011-748X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 ED Entered STN: 12 May 1984
 GI




AB 1-Methyl-3-(2,4-dimethoxyphenyl)- and 1-methyl-3-(3,4-dimethoxyphenyl)propane-1,3-diones were prepared and coupled with diazotized simple and sulfonamide bases in presence of NaOAc to give benzeneazopropone-1,3-diones I (Z = bond, R = H, Me, Cl, Br, NO2, MeO; Z = SO2NH, R = H, Ac, R1C6H4 (R1 = H, Me, Cl, Br, NO2, MeO), pyridyl, (di)methylpyridinyl, methylthiadiazol-2-yl, phenylpyrazol-4-yl, 2-thiazolyl, guanidyl). In vitro screening against *S. aureus*, *Escherichia coli* and *P. pyocyanne* showed considerable activity.
 IT 15520-50-0
 RL: PRP (Properties)

(diazotization and coupling of, with dimethoxyphenylbutanedione)
 RN 15520-50-0 HCPLUS
 CN Benzenesulfonamide, 4-amino-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)




IT 85000-06-2P 85000-09-5P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and bactericidal activity of)
 RN 85000-06-2 HCPLUS
 CN Benzenesulfonamide, 4-[2-[1-(2,4-dimethoxybenzoyl)-2-oxopropyl]diazenyl]-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 85000-09-5 HCAPLUS

CN Benzenesulfonamide, 4-[2-[1-(3,4-dimethoxybenzoyl)-2-oxopropyl]diazenyl]-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L41 ANSWER 17 OF 43 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1982:122735 HCAPLUS Full-text


DOCUMENT NUMBER: 96:122735

ORIGINAL REFERENCE NO.: 96:20157a,20160a

TITLE: Studies in heterocyclic compounds - Part XXXIV:
Synthesis and in vitro screening of some

1,3-diaryl-5-(arylazo-N-substituted
p-sulphamylbenzenazo)dihydro-2-thioxo-4,6(1H,
5H)-pyrimidinediones

AUTHOR(S): Nigam, S. C.; Saharia, G. S.; Sharma, H. R.
CORPORATE SOURCE: Dep. Chem., Univ. Delhi, Delhi, 110007, India
SOURCE: Defence Science Journal (1981), 31(1), 15-22
CODEN: DSJOAA; ISSN: 0011-748X
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 12 May 1984
GI



AB Cyclization of $\text{CH}_2(\text{CO}_2\text{H})_2$ with $\text{p-MeOCH}_2\text{NHCSNH}_2\text{H}_4\text{R-p}$ gave 55.6-60% I ($\text{R} = \text{H}$, OMe , $\text{R}_1 = \text{H}$), which coupled with $\text{R}_2\text{C}_6\text{H}_4\text{NH}_2$ and with $\text{R}_3\text{NHSO}_2\text{C}_6\text{H}_4\text{NH}_2$ to give 68-81% 32 I ($\text{R} = \text{H}$, OMe ; $\text{R}_1 = \text{R}_2\text{C}_6\text{H}_4\text{NH}_2$; $\text{R}_2 = \text{H}$, Me , Cl , Br , NO_2 , MeO) and 63-70% 36 I ($\text{R} = \text{H}$, MeO ; $\text{R}_1 = \text{R}_3\text{NHSO}_2\text{C}_6\text{H}_4\text{NH}_2$; $\text{R}_3 = \text{H}$, Ac , Ph , tolyl , ClC_6H_4 , o-anisyl , $\text{p-O}_2\text{NC}_6\text{H}_4$, pyrimidinyl , $1\text{-phenyl-4-pyrazolyl}$, thiazolyl , etc.). I were subjected to *in vitro* screening at 50 + 100 $\mu\text{g}/\text{me}$ against *Staphylococcus aureus*, *Escherichia coli*, and *Pseudomonas pyocyanne*. I ($\text{R} = \text{OMe}$) were less effective than I ($\text{R} = \text{H}$) and I ($\text{R}_1 = \text{R}_3\text{NHSO}_2\text{C}_6\text{H}_4\text{NH}_2$) were more effective than I ($\text{R}_1 = \text{R}_2\text{C}_6\text{H}_4\text{NH}_2$).


IT 15520-50-0

BL: BCT (Reactant): BACT (Reactant or reagent)

Ref (Reactant), R101 (Reactant or reagent), (diazotization and coupling with thiopyrimidinediones)

BN 15520-50-0 HC API-11S

BN 19920-30-0 NCI-LCS
CN Benzenesulfonamide, 4-amino-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)




IT 81108-30-7p 81108-62-5p

RL: SPN (Synthetic preparation); PREP (Preparation (preparation of))


RN 81108-30-7 HCPLUS

CN Benzenesulfonamide, 4-[2-[hexahydro-1-(4-methoxyphenyl)-4,6-dioxo-3-phenyl-2-thioxo-5-pyrimidinyl]diazenyl]-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)



RN 81108-62-5 HCPLUS

CN Benzenesulfonamide, 4-[2-[hexahydro-1,3-bis(4-methoxyphenyl)-4,6-dioxo-2-thioxo-5-pyrimidinyl]diazenyl]-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)



L41 ANSWER 18 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1981:113982 HCPLUS [Full-text](#)

DOCUMENT NUMBER: 94:113982

ORIGINAL REFERENCE NO.: 94:18467a,18470a

TITLE: Accurate argentometric microdetermination method for chlorine in organic compounds by potentiometric detection of the endpoint

AUTHOR(S): Campiglio, A.; Traverso, G.

CORPORATE SOURCE: Dip. Chim. Farm., Univ. Pavia, Pavia, I-27100, Italy

SOURCE: Mikrochimica Acta (1980), 1(5-6), 495-504

CODEN: MIACAQ; ISSN: 0026-3672

DOCUMENT TYPE: Journal

LANGUAGE: German

ED Entered STN: 12 May 1984


AB The sample was burnt in an O flask and the products were absorbed in an alkaline solution of hydrazine. Chloride was then titrated potentiometrically in H2O-HOAc-iso-ProOH (27:3:5) with 0.01N AgNO3. A Ag2S membrane ion-selective indicator electrode and a double-junction reference electrode were used in combination with a pH-meter to detect the end-point. The standard deviation was 0.09%. Br or I can also be determined under the same conditions, if the titration is carried out in aqueous medium. By means of this method the halogen is not only determined but also identified. The best conditions for the titration of chloride are discussed.

IT 14044-30-5

RL: AMX (Analytical matrix); ANST (Analytical study)
(chlorine determination in, by combustion and potentiometric titration)

RN 14044-30-5 HCPLUS

CN Acetanide, N-[4-[[1-(2-chlorophenyl)-1H-pyrazol-4-yl]amino]sulfonyl]phenyl]- (CA INDEX NAME)



L41 ANSWER 19 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1980:639352 HCPLUS [Full-text](#)

DOCUMENT NUMBER: 93:239352

ORIGINAL REFERENCE NO.: 93:38343a, 38346a

TITLE:

Studies on heterocyclic compounds. Part XXXII.

Synthesis of some

1-(p-methylphenyl)-3-(p-alkoxyphenyl)-5-(arylazo/N-substituted p-sulfamylbenzeneazo)dihydro-2-thioxo-4,6-(1H,5H)-pyrimidinediones as potential antibacterials

AUTHOR(S): Nigam, S. C.; Saharia, G. S.; Sharma, H. R.

CORPORATE SOURCE: Dep. Chem., Univ. Delhi, Delhi, 110007, India

SOURCE: Journal of the Institution of Chemists (India) (1980), 52(2), 75-9

CODEN: JOICAI7; ISSN: 0020-3254


DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 93:239352

ED Entered STN: 12 May 1984

GI



I


AB Thiobarbiturates I (R = OMe, OEt; R1 = C6H4R2, C6H4SO2NHR3-4; R2 = H, Cl, Me, Br, NO2, OMe; R3 = Ac optionally substituted Ph, pyrimidinyl, pyridazinyl, thiazolyl, thiadiazolyl, guanidino) were prepared. Thus 4-MeC6H4NHCSNHC6H4R-4 was treated with CH2(CO2H)2 and the resulting thiobarbiturate treated with R1N2+ salts to give I. I had bactericidal activity which was enhanced in I (R = OEt) relative to I (R = OMe).

IT 75791-60-5P 75791-78-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 75791-60-5 HCPLUS

CN Benzenesulfonamide, 4-[2-[hexahydro-1-(4-methoxyphenyl)-3-(4-methylphenyl)-4,6-dioxo-2-thioxo-5-pyrimidinyl]diazenyl]-N-(1-phenyl-1H-pyrazol-4-yl)-
(CA INDEX NAME)



RN 75791-78-5 HCPLUS

CN Benzenesulfonamide, 4-[2-[1-(4-ethoxyphenyl)hexahydro-3-(4-methylphenyl)-4,6-dioxo-2-thioxo-5-pyrimidinyl]diazenyl]-N-(1-phenyl-1H-pyrazol-4-yl)-
(CA INDEX NAME)



L41 ANSWER 20 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1979:195573 HCPLUS Full-text

DOCUMENT NUMBER: 90:195573

ORIGINAL REFERENCE NO.: 90:30969a,30972a

TITLE: Diffusion-transfer color photographic material

INVENTOR(S): Anpuku, Yoshitaka; Kanbe, Masaru; Takahashi, Yuji; Deguchi, Hidekata; Takahashi, Jiro

PATENT ASSIGNEE(S): Konishiroku Photo Industry Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 23 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 53112735	A	19781002	JP 1977-27851	19770314 <--
PRIORITY APPLN. INFO.:			JP 1977-27851	A 19770314 <--
ED	Entered STN:	12 May 1984		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB A diffusion-transfer color photog. material contains a nondiffusible dye-releasing redox compound (DRR compound) of the general formula I [R = H, OH; R1 = CO2H, SO2NH2, SO3H, C2-9 alkyloxycarbonyl; R2 = H, CO2H, SO2NH2, SO3H; R3 = a diffusible dye moiety which is released from I during development; Z = C2-4 alkylene, Z4SO2Z5 (Z4, Z5 = C1-4 alkylene, and Z5 is bonded to R1 above); Z1 = C2-4 alkylene; Z2 = CO, SO2; Z3 = (Z6Z7)uZ8 (Z6, Z8 = C1-6 alkylene, C6-9 phenylene with/without substituents, alkylenephenylene, or phenylenealkylene having C1-4 alkylene and C6-9 phenylene units; Z7 = CO, O2C, CO2, O, S, NHCO, CONH, NHSO2, SO2NH, SO2, SO; u = 0, 1); m, n, p, q, r, s, t = 0, 1; q + r = 1]. The DRR compound releases a dye having excellent color tone, diffusion characteristics, mordanting properties, and lightfastness. Diffusion-transfer color photog. materials containing the above DRR compds. also exhibit good shelflife. The residual optical d. was .apprx.82%. Thus, a film support was coated with (1) a red-sensitive Ag(Br,I) emulsion, (2) a dispersion consisting of the DRR compound II 8.0, di-Bu phthalate 8.0, and gelatin 14 mg/100 cm², and (3) a protective layer to give a diffusion-transfer photog. photosensitive unit. The photosensitive unit was exposed through an optical wedge, coupled with a conventional image receptor unit, processed with an alkaline processing

solution, the receptor sheet peeled off, and the unit exposed to a fadometer for 72 h.
 IT 69842-53-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 69842-53-1 HCPLUS
 CN Propanamide, N-[3-[[5-amino-3-heptadecyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl]amino]sulfonylphenyl]-3-[[4-[[3-(aminosulfonyl)propyl]amino]-9,10-dihydro-9,10-dioxo-1-anthracyanyl]amino]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



L41 ANSWER 21 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1979:64378 HCPLUS Full-text
 DOCUMENT NUMBER: 90:64378
 ORIGINAL REFERENCE NO.: 90:10103a,10106a
 TITLE: Diffusion-transfer color photographic materials
 INVENTOR(S): Kobe, Masaru; Yasufuku, Yoshitaka; Aoki, Susumu;
 Kunieda, Naoshi
 PATENT ASSIGNEE(S): Konishiroku Photo Industry Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 25 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 53066730	A	19780614	JP 1976-142050	19761126 <--
PRIORITY APPLN. INFO.:				
ED	Entered STN:	12 May 1984	JP 1976-142050	A 19761126 <--
GI				



AB Diffusion-transfer color photog. materials contain a nondiffusible dye-releasing redox compound of the general formula I [R = H, alkyl, substituted alkyl (substituents selected from OH, CO2H, alkoxy, alkylcarbonyl, alkoxycarbonyl, alkylcarbamoyl, alkylcarboxamido, alkylsulfamoyl, and alkylsulfonamido), cycloalkyl, halocycloalkyl, alkylcycloalkyl; and the total number of C atoms in R \leq 14; R1 = H, halogen, an organic monovalent moiety containing \leq 6 C atoms; m = 0-4; Z = C1-8 alkylene; p = 0, 1; Z1 = O, S; q = 0 when p = 0, q = 0, 1 when p = 1; n = 0, 1, Z2, Z4 = C1-6 alkylene, C6-9 phenylene or substituted phenylene, alkylenephenylene with C1-4 alkylene and C6-9 phenylene groups; Z3 = carbonyl, carbonyloxy, oxycarbonyl, carbamoyl, carboxamido, sulfamoyl, sulfonamido, sulfonyl, sulfinyl, O, S; r = 0-3; R2 = dye moiety which is released as a result of oxidation in the presence of an alkaline substance]. The above compds. release dyes having good diffusibility, color tone, mordanting properties, and excellent lightfastness. The diffusion-transfer photog. materials also have an excellent shelf life. Thus, a poly(ethylene terephthalate) film support was coated with (1) a red-sensitive Ag(Br, I) emulsion, (2) a dispersion containing II (8.0 mg/100 cm²), and (3) a protective layer to give a photog. film. The photog. film was sensitometrically exposed, then a receptor unit was placed on the exposed film, and the unit processed with an alkaline processing solution to give cyan images whose optical d. did not change even after 72 h exposure to a fadeometer.

IT 68934-32-7P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 68934-32-7 HCPLUS


CN Benzenesulfonamide, N-[2-[4-[[5-amino-3-heptadecyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl]amino]sulfonyl]phenyl]ethyl]-ar-[19,10-

dihydro-4-[[2-[(methylsulfonyl)amino]ethyl]amino]-9,10-dioxo-1-anthracyanyl]amino]-ar-ethoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




PAGE 3-A


II

L41 ANSWER 22 OF 43 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1977:171321 HCAPLUS Full-text
 DOCUMENT NUMBER: 86:171321
 ORIGINAL REFERENCE NO.: 86:26909a, 26912a
 TITLE: Sulfanilamidopyrazoles. XV. Nitro derivatives of 1-phenyl-4-sulfanilamidopyrazole
 AUTHOR(S): Alberti, C.; Tironi, C.; Bainotti, F.; Deleide, G.


CORPORATE SOURCE: Univ. Torino, Turin, Italy
 SOURCE: Farmaco, Edizione Scientifica (1977), 32(2),
 92-105
 CODEN: FRPSAX; ISSN: 0430-0920
 DOCUMENT TYPE: Journal
 LANGUAGE: Italian
 OTHER SOURCE(S): CASREACT 86:171321
 ED Entered STN: 12 May 1984
 GI




AB Cyclocondensation of 2-, 3- and 4-O2N C6H4NHNH2 and PhCH2CONHCH(CHO)2 and the hydrolysis of I (R = 2-, 3-, 4-O2N; R1 = PhCH2CONH) gave I (R = 2-, 3-, 4-O2N; R1 = NH2). Sulfonation of I (R = 2-, 3-, 4-O2N; R1 = NH2) by 4-AcNH6H4SO2Cl followed by deacetylation gave I (R = 2-, 3-, 4-O2N; R1 = 4-H2NC6H4SO2NH), which had bacteriostatic activity equal to or better than that of 4-sulfanilamidopyrazole against Escherichia coli and Staphylococcus aureus. Also prepared were I (R = 2-, 3-, 4-NH2; R1 = NO2) by hydrogenation of I (R = 2-, 3-, 4-NO2; R1 = NO2) over Pd/C. Diazotization of I (R = 2-NO2, R1 = NO2) gave I (R = H, R1 = NO2).
 IT 62537-83-1P 62537-84-2P 62537-85-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and deacylation of)
 RN 62537-83-1 HCPLUS
 CN Acetamide, N-[4-[[[1-(2-nitrophenyl)-1H-pyrazol-4-yl]amino]sulfonyl]phenyl]- (CA INDEX NAME)




RN 62537-84-2 HCPLUS
 CN Acetamide, N-[4-[[[1-(3-nitrophenyl)-1H-pyrazol-4-yl]amino]sulfonyl]phenyl]- (CA INDEX NAME)




RN 62537-85-3 HCPLUS
 CN Acetamide, N-[4-[[[1-(4-nitrophenyl)-1H-pyrazol-4-yl]amino]sulfonyl]phenyl]- (CA INDEX NAME)




IT 62537-86-4P 62537-87-5P 62537-88-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 62537-86-4 HCPLUS
 CN Benzenesulfonamide, 4-amino-N-[1-(2-nitrophenyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 62537-87-5 HCPLUS
CN Benzenesulfonamide, 4-amino-N-(1-(3-nitrophenyl)-1H-pyrazol-4-yl)- (CA
INDEX NAME)



RN 62537-88-6 HCPLUS
CN Benzenesulfonamide, 4-amino-N-(1-(4-nitrophenyl)-1H-pyrazol-4-yl)- (CA
INDEX NAME)



L41 ANSWER 23 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1975:68756 HCPLUS Full-text
 DOCUMENT NUMBER: 82:68756
 ORIGINAL REFERENCE NO.: 82:10939a,10942a
 TITLE: Pyrazolic sulfanilamides. XIII. Hydroxy derivatives of 1-phenyl-3-sulfanilamidopyrazole and of 1-phenyl-4-sulfanilamidopyrazole
 AUTHOR(S): Alberti, C.; Tironi, C.
 CORPORATE SOURCE: Univ. Torino, Turin, Italy
 SOURCE: Farmaco, Edizione Scientifica (1974), 29(12), 957-66
 CODEN: FRPSAX; ISSN: 0430-0920
 DOCUMENT TYPE: Journal
 LANGUAGE: Italian
 ED Entered STN: 12 May 1984
 GI For diagram(s), see printed CA Issue.
 AB Hydroxy derivs. of 1-phenyl-3-sulfanilamidopyrazole (I) and 1-phenyl-4-sulfanilamidopyrazole (I) were prepared and tested for antibacterial activity. The bacteriostatic activities of all 6 hydroxy derivs. for *Staphylococcus aureus* were greater than those of the parent compds, but only 2 of the derivs. showed enhanced activity toward *Escherichia coli*. The sulfonilamides were prepared from the appropriate 1-(hydroxyphenyl)aminopyrazoles, which were obtained by deethylation of 1-(ethoxyphenyl)aminopyrazoles.
 IT 15520-50-0
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (bactericidal activity of)
 RN 15520-50-0 HCPLUS
 CN Benzenesulfonamide, 4-amino-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)




IT 54371-73-2P 54371-74-3P 54371-75-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and bactericidal activity of)


RN 54371-73-2 HCPLUS

CN Benzenesulfonamide, 4-amino-N-[1-(3-hydroxyphenyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 54371-74-3 HCPLUS

CN Benzenesulfonamide, 4-amino-N-[1-(4-hydroxyphenyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)



RN 54371-75-4 HCPLUS

CN Benzenesulfonamide, 4-amino-N-[1-(2-hydroxyphenyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




IT 54371-82-3P 54371-83-4P 54371-84-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and saponification of)

RN 54371-82-3 HCPLUS


CN Acetamide, N-[4-[(1-(2-hydroxyphenyl)-1H-pyrazol-4-yl)amino]sulfonyl]phenyl- (CA INDEX NAME)



RN 54371-83-4 HCAPLUS
CN Acetamide, N-[4-[(1-(3-hydroxyphenyl)-1H-pyrazol-4-yl)amino]sulfonyl]phenyl- (CA INDEX NAME)



RN 54371-84-5 HCAPLUS
CN Acetamide, N-[4-[(1-(4-hydroxyphenyl)-1H-pyrazol-4-yl)amino]sulfonyl]phenyl- (CA INDEX NAME)



L41 ANSWER 24 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1971:87885 HCPLUS Full-text

DOCUMENT NUMBER: 74:87885

ORIGINAL REFERENCE NO.: 74:14261a,14264a

TITLE: Pyrazolyl sulfanilamides. XI. Ethoxy derivatives of 1-phenyl-3-sulfanilamidopyrazole, 1-phenyl-4-sulfanilamidopyrazole, 1-phenyl-5-sulfanilamidopyrazole, and 1-phenyl-3-methyl-5-sulfanilamidopyrazole

AUTHOR(S): Alberti, Carlo; Tironi, C.

CORPORATE SOURCE: Ist. Chim. Farm. Tossicol., Univ. Pavia, Pavia, Italy
SOURCE: Farmaco, Edizione Scientifica (1971), 26(1), 66-88

DOCUMENT TYPE: CODEN: FRPSAX; ISSN: 0430-0920

LANGUAGE: Journal


ED Entered STN: 12 May 1984

GI For diagram(s), see printed CA Issue.

AB 1-(3-Ethoxyphenyl)-4-sulfanilamidopyrazole (I, R = 3-EtO) was more effective against *Staphylococcus aureus* in vitro than 1-phenyl-4-sulfanilamido-pyrazole (I, R = H) (II). 1-(2-Ethoxyphenyl)-4-sulfanilamido-pyrazole (I, R = 2-EtO) and 1-(4-ethoxyphenyl)-4-sulfanilamido-pyrazole (I, R = 4-EtO) showed less antibacterial activity against *S. aureus* and *Escherichia coli* in vitro than II. 1-(Ethoxy-phenyl)-3-sulfanilamidopyrazoles, 1-(ethoxyphenyl)-5-sulfanilamidopyrazoles, and 1-(ethoxyphenyl)-3-methyl-5-sulfanilamido-pyrazoles were also less effective than the corresponding unsubstituted parents. The above sulfanilamides were prepared according to standard methods from corresponding aminopyrazoles. The aminopyrazoles were prepared by treatment of ethoxyphenyl-hydrazines with acrylonitrile, nitromalondialdehyde (followed by reduction of nitro group), Et ethoxymethylenecyanoacetate or diacetonitrile [followed by cyclization of the hydrazones (III)].IT 30405-92-6P 30405-94-8P 30405-95-9P
30830-08-1P 30830-09-2P 30830-10-5PRL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 30405-92-6 HCPLUS

CN Benzenesulfonamide, 4-amino-N-[1-(3-ethoxyphenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




RN 30405-94-8 HCAPLUS

CN Benzenesulfonamide, 4-amino-N-[1-(2-ethoxyphenyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 30405-95-9 HCAPLUS


CN Benzenesulfonamide, 4-amino-N-[1-(4-ethoxyphenyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 30830-08-1 HCAPLUS
CN Acetamide, N-[4-[[1-(2-ethoxyphenyl)-1H-pyrazol-4-yl]amino]sulfonyl]phenyl- (CA INDEX NAME)



RN 30830-09-2 HCAPLUS
CN Acetamide, N-[4-[[1-(3-ethoxyphenyl)-1H-pyrazol-4-yl]amino]sulfonyl]phenyl- (CA INDEX NAME)



RN 30830-10-5 HCPLUS
 CN Acetamide, N-[4-[[[1-(4-ethoxyphenyl)-1H-pyrazol-4-yl]amino]sulfonyl]phenyl]- (CA INDEX NAME)




L41 ANSWER 25 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1969:36415 HCPLUS Full-text
 DOCUMENT NUMBER: 70:36415
 ORIGINAL REFERENCE NO.: 70:6785a,6788a
 TITLE: Determination of pharmacokinetic constants and
 parameters of chemotherapeutic substances in practice
 AUTHOR(S): Wagner, Wolf Helmut
 CORPORATE SOURCE: Farbwerke Hoechst A.-G., Frankfurt/M.-Hoechst, Fed.
 Rep. Ger.
 SOURCE: Int. Congr. Chemother., Proc., 5th (1967),
 Volume 4, 93-100. Editor(s): Spitzky, K. H. Verlag
 Wiener Med. Akad.: Vienna, Austria.
 CODEN: 20JJA4
 DOCUMENT TYPE: Conference
 LANGUAGE: German
 ED Entered STN: 12 May 1984

AB Computer anal. with a FORTRAN program of the data obtained from a study involving the use of Ma 230 [1-(*p*-methoxyphenyl)-3-methyl-4-sulfanil-*amidopyrazole*] in human subjects, rabbits, sheep, and dogs, and of 2 tuberculostatic compds., isoniazid and T 283 (2-ethyl-3-imino-2,3-dehydrophenanthro[9,10-e]-as-triazine-HCl) in humans, mice, rabbits, and guinea pigs, indicated that this method of pharmacokinetic anal. is a valuable and indispensable aid in the evaluation of exptl. chemotherapy. The information obtained must be reconciled with the results of other test procedures.

IT 23142-47-4

RL: PROC (Process)
(computer anal. of)
RN 23142-47-4 HCPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]- (CA INDEX NAME)



L41 ANSWER 26 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1968:78283 HCPLUS Full-text
 DOCUMENT NUMBER: 68:78283
 ORIGINAL REFERENCE NO.: 68:15110h,15111a
 TITLE: 1-Phenyl-4-alkylaminopyrazole derivatives with
 antipyretic and analgesic action
 INVENTOR(S): Fusco, Raffaello; Bianchi, Mario
 PATENT ASSIGNEE(S): Francesco Vismara Societa per Azioni
 SOURCE: Fr. M., 6 pp.
 CODEN: FMXXAJ
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR M4086	---	19660516	FR	<--
DE 1620658			DE	
GB 1100754			GB	
US 3398158		19680820	US 1965-433175	19650216 <--
PRIORITY APPLN. INFO.:			IT	19640219 <--

OTHER SOURCE(S): MARPAT 68:78283

ED Entered STN: 12 May 1984

GI For diagram(s), see printed CA Issue.

AB I possess antipyretic and analgesic activity. R is H, Me, or HOCH₂; R₁ is H or Me; X is H, halogen, lower alkyl alkoxy, alkylamino, or dialkylamino, OH, NH₂, acetylamino, or NO₂; R₂ is H, lower alkyl or CH₂SO₃M where M is alkaline metal and cycloalkyl. E.g., 1.6 g. 1-phenyl-4-aminopyrazole (II) in 75 ml. absolute EtOH was treated with 2.4 ml. 30% alc. CH₂O and 0.15 g. Raney Ni, and hydrogenated under pressure to give 1.5 g. 1-phenyl-4-dimethylaminopyrazole (III), b.p. 100°, m. 45-7°. (hydrochloride m. 172-4°). A mixture of 47.75 g. II, 151.3 g. Me₂SO₄, and 70 g. Na₂CO₃ in 470 ml. MeOH was refluxed 7-8 hrs. to give 37 g. III. Alternatively, 19 g. II, 228 g. MeBr, and 33.2 g. K₂CO₃ in MeOH gave the quaternary salt which was pyrolyzed at 220-5° to give 14.8 g. III. Replacement of MeBr by CH₂:CHCH₂Br gave 1-phenyl-4-diallylaminopyrazole (hydrochloride m. 116-18°). Also prepared were I (X, R, R₁, R₂ = R₃, b.p., and m.p. HCl salt): H, Me, Me, H, b.p. 75°, 178-80°; H, H, Me, Me, b.p. 0.05 98-103°; 193-5°; H, Me, Me, Me, -, -; H, H, H, Et, b.p. 124-5°, m. 148-50°. II (6.4 g.) in 20 ml. anhydrous pyridine with 8.4 g. p-MeC₆H₄SO₂Cl gave 11.4 g. 1-phenyl-4-(p-toluenesulfonamido)pyrazole (IV), m. 180-2°. IV (4.7 g.) in 10% NaOH with 1.9 g. Me₂SO₄ gave 3.3 g. 1-phenyl-4-methyl-p-toluenaminopyrazole (V), m. 81-3°. V (10.8 g.) was refluxed in 86 ml. dilute H₂SO₄ to give 4.4 g. 1-phenyl-4-methylaminorazole (hydrochloride m. 178-80°). Similarly from 9.4 g. IV was obtained 8.1 g. 1-phenyl-4-ethyl-p-tosylaminopyrazole, m. 137-9°, which with H₂SO₄ gave 1-phenyl-4-ethylaminopyrazole, b.p. 125-7° (hydrochloride m. 223-5°). Similarly prepared were the following I (R = R₁ = H, X, R₂, R₃, b.p., and m.p. HCl salt given): H, iso-Pr, H, b.p. 120°, 188-90°; H, 2-pentyl, H, b.p. 135-8°, 152-4°; H, cyclopentyl, H, b.p. 130-5°, 190-2°; H, 4-cyclohexyl, H, b.p. 1 153-6° (m. 165-7°), 259-61°; H, 4-cycloheptyl, H, b.p. 1 140-50° (m. 58-60°), 189-91°; H, Me, Et, b.p. 1 118-22°, 164-6°; H, Me, Iso-Pr, b.p. 1 115-17°, 170-2°; 2-Me, Me, Me, -, 185-6°; 2,6-Me₂, Me, Me, -, 201-3°; 4-HO, Me, Me, -, 218-20°; 4-H₂N, Me, Me, -, - (di-HCl salt m. 224-5°); 4-Me₂N, Me, Me, -, 220-2°. III with aqueous CH₂O solution was refluxed 2 hrs. to give 1-phenyl-4-dimethylamino-5-hydroxymethylpyrazole.


IT 21274-87-3P 21274-90-8P

RL: SPN (Synthetic preparation); PRP (Properties); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)


(1-Phenyl-4-alkylaminopyrazole derivatives with antipyretic and analgesic action)

RN 21274-87-3 HCPLUS


CN Benzenesulfonamide, N,4-dimethyl-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)



RN 21274-90-8 HCAPLUS
 CN Benzenesulfonamide, N-ethyl-4-methyl-N-(1-phenyl-1H-pyrazol-4-yl)- (CA
 INDEX NAME)



IT 17551-11-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 17551-11-0 HCAPLUS
 CN Benzenesulfonamide, 4-methyl-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX
 NAME)



L41 ANSWER 27 OF 43 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1967:115640 HCAPLUS Full-text
 DOCUMENT NUMBER: 66:115640
 ORIGINAL REFERENCE NO.: 66:21487a,21490a
 TITLE: Pyrazolesulfanilamides. VIII. Chloro derivatives of
 1-phenyl-4-sulfanilamidopyrazole
 AUTHOR(S): Alberti, Carlo; Tironi, C.
 CORPORATE SOURCE: Univ. Pavia, Pavia, Italy
 SOURCE: Farmaco, Edizione Scientifica (1966),
 21(12), 883-91
 CODEN: FRPSAX; ISSN: 0430-0920

DOCUMENT TYPE: Journal
 LANGUAGE: Italian

ED Entered STN: 12 May 1984
 GI For diagram(s), see printed CA Issue.


AB Compds. of the general formula I are prepared and exhibit a low bacteriostatic activity against *in vitro* grown *Staphylococcus aureus* and *Escherichia coli*. A mixture of 3.5 g. o-C1C6H4NNH2.HCl, 30 ml. EtOH, and 3.1 g. Na+ C(NO2)(CHO)2-H2O is heated 2 hrs. to give 65% 1-(o-chlorophenyl)-4-nitropyrazole (II), m. 101-2°. Similarly prepared are (m.p. and % yield given): 1-(m-chlorophenyl)-4-nitropyrazole, 112-13°, 63; 1-(p-chlorophenyl)-4-nitropyrazole, 164-5°, 88; 1-(2,4-dichlorophenyl)-4-nitropyrazole, 194-5°, 60. A mixture of 2.2 g. II, 20 ml. EtOH, and 10 ml. 85% N2H4.H2O is heated 25 min. in the presence of 0.1 g. 5% Ru/C to give 62% 1-(o-chlorophenyl)-4-aminopyrazole (III), m. 80-1°. Similarly prepared are (m.p. and % yield given): 1-(m-chlorophenyl)-4-aminopyrazole, 69-70°, 69; 1-(p-chlorophenyl)-4-aminopyrazole, 93-4°, 62; 1-(2,4-dichlorophenyl)-4-aminopyrazole, 104-5°, -. A mixture of 1.9 g. III, 5 ml. pyridine, and 2.33 g. p-AcNH6H4S02Cl is heated to give 3.72 g. 1-(o-chlorophenyl)-4-(p-acetamidobenzenesulfonamido)pyrazole (IV), m. 230-1°. Similarly prepared are (m.p. given): 1-(m-chlorophenyl)-4-(p-acetamidobenzenesulfonamido)pyrazole, 211-12°; 1-(p-chlorophenyl)-4-(p-acetamidobenzenesulfonamido)pyrazole, 221-2°; 1-(2,4-dichlorophenyl)-4-(p-acetamidobenzenesulfonamido)pyrazole, 192-3°. A mixture of 3.9 g. IV and 50 ml. 5% NaOH is heated 3 hrs. to give 3.0 g. 1-(o-chlorophenyl)-4-(p-aminobenzenesulfonamido)pyrazole, m. 155-6°. Similarly prepared are (m.p. given): 1-(m-chlorophenyl)-4-(p-aminobenzenesulfonamido)pyrazole, 195-6°; 1-(p-chlorophenyl)-4-(p-aminobenzenesulfonamido)pyrazole, 223-4°; 1-(2,4-dichlorophenyl)-4-(p-aminobenzenesulfonamido)pyrazole, 164-5°.

IT 10476-55-8P 10476-56-9P 10476-57-0P
 10476-58-1P 14044-30-5P 14044-31-6P
 14044-32-7P 14044-33-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 10476-55-8 HCPLUS

CN Benzenesulfonamide, 4-amino-N-[1-(2-chlorophenyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 10476-56-9 HCPLUS


CN Benzenesulfonamide, 4-amino-N-[1-(3-chlorophenyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 10476-57-0 HCAPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(4-chlorophenyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 10476-58-1 HCAPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(2,4-dichlorophenyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 14044-30-5 HCPLUS
CN Acetamide, N-[4-[(1-(2-chlorophenyl)-1H-pyrazol-4-yl)amino]sulfonyl]phenyl- (CA INDEX NAME)




RN 14044-31-6 HCPLUS
CN Acetamide, N-[4-[(1-(3-chlorophenyl)-1H-pyrazol-4-yl)amino]sulfonyl]phenyl- (CA INDEX NAME)



RN 14044-32-7 HCAPLUS
CN Acetamide, N-[4-[[1-(4-chlorophenyl)-1H-pyrazol-4-yl]amino]sulfonyl]phenyl]- (CA INDEX NAME)



RN 14044-33-8 HCAPLUS
CN Acetamide, N-[4-[[1-(2,4-dichlorophenyl)-1H-pyrazol-4-yl]amino]sulfonyl]phenyl]- (CA INDEX NAME)



L41 ANSWER 28 OF 43 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1965:431646 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 63:31646
 ORIGINAL REFERENCE NO.: 63:5625g-h,5626a-d
 TITLE: Pyrazoles. XLIII. Some aminopyrazoles
 AUTHOR(S): Grandberg, I. I.; Tabak, S. V.
 CORPORATE SOURCE: M. V. Lomonosov State Univ., Moscow
 SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1965
), (1), 112-15
 CODEN: KGSSAQ; ISSN: 0132-6244
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 ED Entered STN: 22 Apr 2001
 GI For diagram(s), see printed CA Issue.
 AB cf. CA 62, 16226f. Some derivs. of aminopyrazoles were prepared to test their biol. activity. To prepare 1-(N-substituted)-3-methyl-5- aminopyrazoles a substituted hydrazine was dissolved in 2N HCl, and to the stirred solution at 80° a small excess of MeC(:NH)CH₂CN was slowly added. After boiling 10 min., some concentrated HCl was added and boiled further 20 min. When cooled, the mixture was alkalized with NaOH; the product was extracted with C₆H₆ and vacuum distilled. Benzenesulfonylamine derivs. resulted, when PhSO₂Cl was dropped in 15 min. into a cooled equimolar amount of aminopyrazole suspended in absolute pyridine. After 24 hrs. at laboratory temperature the mixture was heated 30 min. on a boiling water bath, then poured into 2N HCl and agitated. Separated crystals (or oil) were crystallized from 60% MeOH and then from C₆H₆-petr. ether (2:1). To obtain trichloroacetamidopyrazoles a 25% excess C₁₃CCOCl was dropped slowly into a cooled solution of aminopyrazole in absolute pyridine; after 4 hrs. MeOH was added, boiled 10 min., filtered, a part of solvent distilled and replaced by H₂O. The separated crystals were crystallized from C₆H₆-petr. ether (1:2). Yields and m.p. of I are tabulated, with X = AcNH; Y = C₁₃CCONH; Z = PhSO₂NH; Am = n-amyl; Q = β -(pyridyl-2)-ethyl; X = β -(pyridyl-4)-ethyl; Z = β -diethylaminoethyl. Thin layer chromatography characteristics on Al203 and silica gel are given. R₁, Substituents, R₃, R₄, R₅, % yield, M.p.; Q, Me, H, NH₂, 61, 50°; X, Me, H, NH₂, 70, 47°; Am, Me, H, NH₂, 76, 49° (1); Z, Me, H, NH₂, 69, -(2); Ph, X, H, H, 67, 130°; Ph, Y, H, H, 70, 130°; Ph, Z, H, H, 39, 88°; Ph, H, X, H, 58, 120°; Ph, H, Y, H, 51, 168°; Ph, H, Z, H, 41, 143°; Ph, H, H, X, 67, 86°; Ph, H, H, Y, 77, 137°; Ph, H, H, Z, 40, 164°; Ph, Me, H, X, 49, 109°; Ph, Me, H, Y, 55, 134°; Ph, Me, H, Z, 48, 154°; (1) b22 178-9°; (2) b16 180-3°. Further

1-amyl-3,5-dimethyl-4-aminopyrazole (II) resulted, when the corresponding 4-NO derivative was reduced by NH₂NH₂.H₂O (yield 61%, b6 154-6°, n_{20D} 1.5025, d₂₀₄ 0.9728). Then II, dissolved in 85% HCO₂H, was boiled 10 hrs. with paraformaldehyde, in presence of a Ni catalyst. The excess of HCO₂H was distilled, the mixture alkalinized and extracted with C₆H₆ to give 1-amyl-3,5-dimethyl-4-dimethylaminopyrazole (yield 59%, b12 152-4°, n_{20D} 1.4780, d₂₀₄ 0.9231). To obtain β -diethylaminoethylhydrazine, boiling NH₂NH₂.H₂O was treated with a concentrated aqueous solution of (C₁CH₂CH₂)₃N.HCl. After 3 hrs. refluxing the mixture was cooled, alkalinized with NaOH, and extracted with ether (60 hrs.). Distillation gave raw product in 50% yield, b60 102-14°; redistn. gave b56 109°, n_{20D} 1.4479. Finally β -pyridylhydrazines were obtained in >82% yield, when boiling 7 hrs. a mixture of NH₂NH₂.H₂O, MeOH, and 2- or 4-vinylpyridine, and then distilling in vacuo.


IT 2574-76-7P, Benzenesulfonamide, N-(1-phenylpyrazol-4-yl)-

RL: PREP (Preparation)

(preparation of)

RN 2574-76-7 HCAPLUS

CN Benzenesulfonamide, N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)



L41 ANSWER 29 OF 43 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1964:476534 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 61:76534

ORIGINAL REFERENCE NO.: 61:13299h,13300a-h,13301a

TITLE: Sulfanilamidopyrazoles. VI.

1-(Tolyl)sulfanilamidopyrazoles derived from aminopyrazoles

AUTHOR(S): Alberti, C.; Tironi, C.

CORPORATE SOURCE: Univ. Pavia, Italy

SOURCE: Farmaco, Edizione Scientifica (1964), 19(7), 618-37

CODEN: FRPSAX; ISSN: 0430-0920

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 61:76534

ED Entered STN: 22 Apr 2001

GI For diagram(s), see printed CA Issue.

AB The 1-(tolyl) derivs. of 3,4-(p-aminobenzenesulfonamido)pyrazoles and of 3-methyl-5-(p-aminobenzenesulfonamido)pyrazoles were prepared and tested in vitro against *Staphylococcus aureus* and *Escherichia coli*. o-Tolylhydrazine (Ia) (12.2 g.) and 2-3 drops choline hydrate was slowly treated with stirring and cooling with 4.8 g. freshly distilled acrylonitrile at 1.ltorsim.40-50°, the mixture heated 1 hr. on a steam bath, the brown oil refluxed 30 min. with 20 cc. concentrated HCl and 200 cc. H₂O, the solution cooled to room temperature, treated with C, and filtered, and the filtrate alkalinized with 10% NaOH to give 51% 1-(o-tolyl)-3-amino-2-pyrazoline (I), needles, m. 93-4° (ligroine). Similarly, m-tolylhydrazine gave 1-(m-tolyl)-3-amino-2-pyrazoline


(II), m. 119-20°; p-tolylhydrazine gave 70% the 1-(p-tolyl) analog (III) of II, m. 138-9° (C₆H₆-ligroine). m-Nitrobenzaldehyde (7.55 g.) was treated with 8 g. I in 12 cc. EtOH and 2 cc. AcOH 2 hrs. at room temperature, the mixture cooled with ice, and the precipitated filtered off to give 80% 1-(o-tolyl)-3-(m-nitrobenzylideneamino)-2-pyrazoline (IV), deep-red, m. 128-9° (EtOH). Similarly, in boiling PhMe, II gave 86% the 1-(m-tolyl) analog of IV (V), red, m. 191-2° (dioxane), and III in EtOH and AcOEt gave 93% the 1-(p-tolyl) analog (VI) of IV, red, m. 198-9° (C₆H₆). Condensing 7 g. p-C₁C₆H₄CHO with 8 g. III in EtOH and AcOH gave 83% 1-(p-tolyl)-3-(p-chlorobenzylideneamino)-2-pyrazoline (VII), red, m. 229-30° (aqueous dioxane). IV (10.2 g.) in 350 cc. Me₂CO, 2 cc. 2% aqueous MnSO₄, and 2 cc. lime-water was treated by stirring with finely ground KMnO₄ 2 hrs. on boiling water-bath, and the solution filtered and evaporated in vacuo to give 57% 1-(p-tolyl)-3-(m-nitrobenzamido)pyrazole (VIII), light yellow, m. 145-6° (EtOH). Similarly, V gave 80% 1-(m-tolyl)-3-(m-nitrobenzamido)pyrazole (IX), yellow, m. 159-60° (EtOH); VI gave 78% the 1-(p-tolyl) analog (X) of IX, yellow, m. 180-1° (EtOH). VII gave 65% 1-(p-tolyl)-3-(p-chlorobenzamido)pyrazole (XI), light yellow, m. 179-80° (EtOH). VIII (3.22 g.) in 20 cc. EtOH, 20 cc. concentrated HCl, and 20 cc. iso-PrOH saturated with HCl gas refluxed 3 hrs., and treated with C, and filtered, the filtrate evaporated in vacuo, the residue diluted with 100 cc. H₂O and extracted with Et₂O, the aqueous layer made alkaline with 10% NaOH and extracted with Et₂O, the solvent evaporated, and the oily residue distilled at low pressure and crystallized from ligroine and Et₂O gave 86% 1-(o-tolyl)-3-aminopyrazole (XII), m. 58-9°. Similarly IX gave 54% 1-(m-tolyl)-3-aminopyrazole, m. 47-8°, and X gave 94% 1-(p-tolyl)-3-aminopyrazole (XIII), m. 104-5° (ligroine). XIII was similarly obtained also from XI. Ia.HCl (7.9 g.) in 30 cc. EtOH was treated with stirring with 7.85 g. O₂NCH(CHO)2.H₂O, the mixture heated 2 hrs. on a steam bath, and the solvent evaporated to give 86% 1-(otolyl)-4-nitropyrazole (XIV), yellow, m. 69-70° (ligroine). Similarly, using m-tolylhydrazine gave 87% 1-(m-tolyl)-4-nitropyrazole, yellow, m. 76-7° (ligroine). 1-(p-Tolyl)-4-nitropyrazole, yellow, m. 91-2° (ligroine), yield 78%. Pd-C (10%, 0.25 g.) and 6 g. 85% hydrazine hydrate were added to a boiling solution of 4 g. XIV in 15 cc. EtOH. After completing the reduction, the solution was filtered and evaporated in vacuo, the oily residue was distilled at low pressure and purified through its hydrochloride. 1-(o-Tolyl)-4-aminopyrazole-HCl m. 233-4°; free base m. 40-1° (petr. ether). Similarly was prepared 1-(m-tolyl)-4-aminopyrazole-HCl m. 243-4° (aqueous EtOH-Et₂O); 79% free base m. 57-8° (gasoline). Also obtained was 79% 1-(p-tolyl)-4-aminopyrazole, m. 89-90° (gasoline). MeC(:NH)CH₂CN (XV) (8.2 g.) was added to 12.2 g. Ia in 15 cc. absolute EtOH at 50-60° and the mixture heated 1.5 hrs. on a steam bath and cooled to give 59% of the o-tolylhydrazone (XVI) of acetoacetonitrile (XVII), m. 114-15° (EtOH), λ 4.5 μ . Similarly were prepared the following hydrazones of XVII: 66% m-tolylhydrazone, yellow, m. 134-5° (EtOH); and 64% p-tolylhydrazone, gold yellow, m. 124-5° (EtOH). XVI (18.7 g.) and 20 cc. concentrated HCl heated 0.5 hr. on a steam bath gave 87% 1-(o-tolyl)-3-methyl-5-aminopyrazole-HCl (XVIII), m. 114-15°; free base m. 89-90° (gasoline). Will (12 g.) was also prepared from 15.8 g. Ia in 20 cc. concentrated HCl and 80 cc. H₂O treated with 8 g. XV. The m- and p-isomers of XVIII were prepared by both methods; 86% 1-(m-tolyl) analog of XVIII, m. 78-9° (gasoline) [97% HCl salt m. 195-6° (absolute EtOH-Et₂O)]; 99% 1-(p-tolyl) analog, m. 119-20° (ligroine) [84% HCl salt m. 218-19° (absolute EtOH + Et₂O)]. XII (1.73 g.) in 5 cc. C₅H₁₁N was treated with 2.33 g. p-acetamidobenzenesulfonyl chloride (XIX), the mixture refluxed 0.5 hr. and treated with 150 cc. 2N HCl and ice, and the whitish product purified by dissolving in 2% NaOH, precipitating with dilute HCl, and crystallizing from dilute EtOH. Similarly were prepared the following XX (R = NH₂O₂C₆H₄-NHAC-p, R₂ = Me) (position R, R₁, position R₂, m.p., % yield given): 3, H, m. 167-8°, 95%; 3, H, m. 208-9°, 87%; 3, H, p. 215-16°, 95%; 4, H, o, 229-30°, 91%; 4, H, m. 197-8°, 75%; 4, H, p. 210-11°, 93%; 5, Me, o, 229-30°, 87%; 5, Me, p,

212-13°, 91; 5, Me, m, 115-16°, 81. XXI (1.85 g.) hydrolyzed with 15 cc. 5% NaOH 3 hrs. at reflux and the mixture cooled and acidified with AcOH gave 1.5 g. 1-(o-tolyl)-3-(p-aminobenzenesulfonamido)pyrazole (XXII), m. 144-5° (dil EtOH) (method A). XXII was obtained by an alternate method of acylating 1.7 g. I in 15 cc. anhydrous C5H5N with 5.4 g. XIX and hydrolyzing the crude compound obtained with 5% NaOH (method B). By method A and B were prepared the following XX (R = $\text{NHSO}_2\text{C}_6\text{H}_4\text{NH}_2$ -p, R2 = Me) (method, position R, R1, position R2, m.p., % yield given): A and B, 3, H, m, 171-2°, 82; A and B, 3, H, p, 215-16°, 93; A, 4, H, o, 166-7°, 85; A, 4, H, m, 166-7°, 85; A, 4, H, p, 218-19°, 80; A, 5, Me, o, 192-3°, 85; A, 5, Me, m, 190-1°, 85; A, 5, Me, p, 202-3°, 83. The bacteriostatic activity against *S. aureus* was, as a rule, greater than that against *E. coli*. A comparison between the bacteriostatic activity of the corresponding members of 3-, 4-, and 5-sulfonamidopyrazoles has shown a decrease of activity in the order: 5-, 3- and 4-sulfanilamidopyrazoles (for unsubstituted members and their Me derivs.).

IT 15520-50-0, Sulfanilamide, N1-(1-phenylpyrazol-4-yl)-
94571-61-6, Sulfanilamide, N1-[1-(m-methoxyphenyl)pyrazol-4-yl]-
94571-63-8, Sulfanilamide, N1-[1-(o-methoxyphenyl)pyrazol-4-yl]-
94571-65-0, Sulfanilamide, N1-[1-(p-methoxyphenyl)pyrazol-4-yl]-
(bactericidal activity of)


RN 15520-50-0 HCPLUS

CN Benzenesulfonamide, 4-amino-N-(1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)




RN 94571-61-6 HCPLUS


CN Benzenesulfonamide, 4-amino-N-[1-(3-methoxyphenyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 94571-63-8 HCAPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(2-methoxyphenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




RN 94571-65-0 HCAPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(4-methoxyphenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




IT 93880-78-5P, Acetanilide, 4'-(1-o-tolylpyrazol-4-yl)sulfamoyl]-
 93880-80-9P, Acetanilide, 4'-(1-p-tolylpyrazol-4-yl)sulfamoyl]-
 95156-99-3P, Acetanilide, 4'-(1-m-tolylpyrazol-4-yl)sulfamoyl]-
 RL: PREP (Preparation)
 (preparation of)
 RN 93880-78-5 HCPLUS
 CN Acetamide, N-[4-[(1-(2-methylphenyl)-1H-pyrazol-4-
 yl)amino]sulfonyl]phenyl- (CA INDEX NAME)



RN 93880-80-9 HCPLUS
 CN Acetamide, N-[4-[(1-(4-methylphenyl)-1H-pyrazol-4-
 yl)amino]sulfonyl]phenyl- (CA INDEX NAME)



RN 95156-99-3 HCAPLUS
 CN Acetamide, N-[4-((1-(3-methylphenyl)-1H-pyrazol-4-yl)amino)sulfonyl]phenyl- (CA INDEX NAME)



L41 ANSWER 30 OF 43 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1964:432385 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 61:32385
 ORIGINAL REFERENCE NO.: 61:5633f-h,5634a-c
 TITLE: Pyrazole sulfanilanides
 AUTHOR(S): Alberti, C.; Tironi, C.
 CORPORATE SOURCE: Univ. Pavia, Italy
 SOURCE: Farmaco, Edizione Scientifica (1964), 19(5),
 459-73
 CODEN: FRPSAX; ISSN: 0430-0920
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 OTHER SOURCE(S): CASREACT 61:32385
 ED Entered STN: 22 Apr 2001
 GI For diagram(s), see printed CA Issue.

AB A boiling solution of 36.6 g. 4-nitroveratrole in 75 cc. EtOH containing 0.6 g. 10% Pd-C was treated with 35 g. 85% N2H4.H2O. After evolution of N, the solution was refluxed 30 min., 4.5 g. N2H4.H2O and a few mg. of Pd-C were added, and boiling was continued for 10 min. The process was repeated until the solution was pale yellow to give 4-aminoveratrole (I), b24 172-4°, m. 86°. A solution of 3.1 g. Na in 85 cc. dry EtOH and 20.4 g. 3,4-dimethoxyphenylhydrazine (II) (obtained from I) was refluxed 30 min., 5.3 g. freshly distilled CH2:CHCN added slowly, and the mixture refluxed 3 hrs. to give 58% N-(3,4-dimethoxyphenyl)-3-amino-2-pyrazoline (III), m. 185-6°. m-Nitrobenzaldehyde (0.05 mole) in 15 cc. EtOH and 0.05 mole III in 250 cc. EtOH containing 5 cc. AcOH was heated 24 hrs. at 100° to give 88% N-(3,4-dimethoxyphenyl)-3-(3-nitrobenzylideneamino)-2-pyrazoline (IV), m. 1867° (toluene). Similarly, the 3-(p-chlorobenzylideneamino) analog (V), m. 171-2°, was prepared in 64% yield. A solution of 0.02 mole IV in 450 cc. Me2CO containing 3 cc. 2% aqueous MnSO4 and 3 cc. Ca(OH)2 (to pH 7-8) was treated with 4.2 g. powdered KMnO4. After being stirred and boiled for 2 hrs. further KMnO4 was added and boiling was continued until a neg. pyrazoline reaction was obtained to give 48% VI (R = m-O2NC6H4CONH, R1 = R2 = H) (VIa), m. 214-15°, also prepared from m-O2NC6H4COCl and N(3,4-dimethoxyphenyl)-3-aminopyrazole (VII) in pyridine. Similar oxidation of V gave 50-6% VI (R = p-ClC6H4CONH, R1 = R2 = H) (VIIa), m. 214-15°, which was also prepared by pchlorobenzoylation of VII. Refluxing 0.005 mole VIIa in 30 cc. EtOH with 30 cc. concentrated HCl 3 hrs. gave 80% VII, m. 123-4° (Ligroine-Et2O). VII was also prepared by similar hydrolysis of VIIa. VII (0.05 mole) in 8 cc. pyridine was slowly treated with 0.05 mole p-AcNHCO6H4SO2Cl (VII) and heated 30 min. at 95° to give 86% VI (R = p-AcNHCO6H4SO2NH, R1 = R2 = H), m. 161-2°, which was hydrolyzed with 5% NaOH by refluxing for 3 hrs. to give 93% VI (R = p-H2NC6H4SO2NH, R1 = R2 = H), m. 112-13°. VI (R = R2 = H, R1 = NO2), m. 147-8°, was prepared in 87% yield by adding 0.1 mole NaC(NO2)(CHO)2 slowly with stirring to 0.1 mole II.HCl in 300 cc. 80% aqueous EtOH and heating at 100° for 1.5 hrs. Reduction of this nitro compound with 10% Pd-C and N2H4 as above gave 59% VI (R = R2 = H, R1 = NH2), m. 116-17°. Reaction of this amine with VIII in pyridine gave 62% VI (R = R2 = H, R1 = p-AcNHCO6H4SO2NH), m. 1989°. A mixture of 0.01 mole MeC(:NH)CH2CN (IX) in 20 cc. EtOH and 0.1 mole II in 20 cc. EtOH and 2 cc. AcOH was heated at 40-50° for a few min. until clear to give 67% 3,4-(MeO)2C6H3HNH:CHMeCH2 CN (X), m. 106-8°. When 11.65 g. X in 50 cc. concentrated HCl was evaporated to dryness at 100° 90% the hydrochloride of VI (R = Me, R1 = H, R2 = NH2), m. 242°, was obtained; the free base m. 180-2°. The hydrochloride was also prepared in 70% yield from 0.02 mole II in 25% aqueous HCl and 1.65 g. IX followed by 4 cc. concentrated HCl after boiling for 10 min. and cooling to 0°. VI (R = Me, R1 = H, R2 = p-H2NC6H4SO2NH), m. 151-2° (decomposition), was prepared in 52% yield from VI (R = Me, R1 = H, R2 = NH2) and VII in pyridine followed by hydrolysis of the acetyl group with 5% aqueous NaOH solution.

IT 94711-52-1P, Sulfanilamide,

N1-[1-(3,4-dimethoxyphenyl)pyrazol-4-yl]- 98196-49-7P,


Acetanilide, 4'-[1-(3,4-dimethoxyphenyl)pyrazol-4-yl]sulfamoyl]-

RL: PREP (Preparation)


(preparation of)

RN 94711-52-1 HCPLUS

CN Benzenesulfonamide, 4-amino-N-[1-(3,4-dimethoxyphenyl)-1H-pyrazol-4-yl]-
(CA INDEX NAME)



RN 98196-49-7 HCPLUS
 CN Acetamide, N-[4-[[1-(3,4-dimethoxyphenyl)-1H-pyrazol-4-yl]amino]sulfonyl]phenyl- (CA INDEX NAME)



L41 ANSWER 31 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1964:432386 HCPLUS [Full-text](#)
 DOCUMENT NUMBER: 61:32386
 ORIGINAL REFERENCE NO.: 61:5634c-f
 TITLE: Substituted 2-sulfanilamidoazoacetates and their
 cyclization
 AUTHOR(S): Prakash, Anil; Gambhir, I. R.
 CORPORATE SOURCE: Meerut Coll.
 SOURCE: Journal of the Indian Chemical Society (1964
), 41(3), 229-30
 CODEN: JICSAH; ISSN: 0019-4522
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 ED Entered STN: 22 Apr 2001


AB cf. CA 61, 1848e. Reactions of 2-sulfanilamidobenzenes used earlier (loc. cit.) were applied to other 2-sulfanilamidoarenes (I). Thus, a diazotized solution of 0.01 mole I was shaken vigorously with a cooled mixture of 0.7 mole NaOAc, 0.01 mole AcCH₂CO₂Et, 25 ml. H₂O, and 25 ml. EtOH, and the product crystallized from AcOH to give 70-80% 2-sulfanilamidoareneazoacetoacetates (II), which on heating with dilute HCl in EtOH yielded the corresponding MeCOCHO 2-sulfanilamidophenylhydrazones (III). II (0.01 mole) refluxed separately with 0.01 mole H₂NCONHH₂.HOAc, PhNHH₂, H₂NNH₂.H₂O, or HONH₂.HOAc in EtOH and AcOH were cyclized to 64-69% 3-methyl-4-(2-sulfanilamidoareneazo)pyrazol-5-one-1-carboxamide (IV), 70-75% 1-phenyl-3-methyl-4-(2-sulfanil-amidoareneazo)pyrazol-5-one (V), 3-methyl-4-(2-sulfanilamido-areneazo)pyrazol-5-one (VI), or 3-methyl-4-(2-sulfanilamido-areneazo)isoxazol-5-one (VII), resp. (arene, m.p. II, m.p. II 2,4-dinitrophenylhydrazone, m.p. III, m.p. IV, m.p. V, m.p. VI, and m.p. VII given): thiazole, 155°, 255°, 305°, 275°, 219°, 275°, 240°; methylthiazole, 181°, 233°, 318°, 280°, 225°, 280°, 246°; pyridine, 170°, 213°, 311°, 280°, 227°, 260°, 200°; pyrimidine, 105°, 214°, 286°, 225°, 222°, 270°, 235°; 4-methylpyrimidine, 143°, 208°, 300°, 240°, 231°, 260°, 229°; 4,6-dimethylpyrimidine, 172°, 250°, 302°, 260°, 242°, 245°, 205°; pyrazine, 180°, 246°, 314°, 215°, 210°, 254°, 227°.

IT 94711-52-1

(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 94711-52-1 HCAPLUS

CN Benzenesulfonamide, 4-amino-N-[1-(3,4-dimethoxyphenyl)-1H-pyrazol-4-yl]-
(CA INDEX NAME)



L41 ANSWER 32 OF 43 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1964:3141 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 60:3141

ORIGINAL REFERENCE NO.: 60:515c-d

TITLE: Pyrazoles. XXXVII. Chromatographic separation of aminopyrazoles

AUTHOR(S): Grandberg, I. I.; Tabak, S. V.; Faizova, G. K.; Kost, A. N.

SOURCE: *Zhurnal Obshchey Khimii* (1963), 33(8),

2585-6

CODEN: ZOKHA4; ISSN: 0044-460X

DOCUMENT TYPE:

Journal

LANGUAGE:

Unavailable

ED Entered STN: 22 Apr 2001


AB cf. CA 58, 3290f; 59, 1615b; preceding abstract. It was shown that aminopyrazoles may be separated by paper chromatography or thinlayer chromatography on Al2O3. The Rf values for paper chromatographic separation are tabulated for 13 aminopyrazoles in such solvent systems as: 20:1:40 iso-PrOH-CHCl3-2N NH4OH; 1:1 MeOH-10% HCO2H; 25:5:2 tert-BuOH-petr. ether-2N NH4OH; MeNO2-MeOH-2N NH4OH (63:5:2); and similar proportions of MeNO2-MeOH-10% HCO2H; and 20:4:2 iso-AmOH-HCO2H-H2O. For chromatography on Al2O3 the following systems were employed (Rf values tabulated for 12 representative aminopyrazoles): 1:1 C6H6-CHCl3; 1:3 C6H6-CHCl3; 1:20 C6H6-CHCl3; 25:1 C6H6-MeOH; 15:1 C6H6-MeOH; 10:1 C6H6-MeOH; and 1:5 petr. ether-CHCl3.

IT 94711-31-6P, Sulfanilamide,

N1-(3,5-dimethyl-1-phenylpyrazol-4-yl)-

RL: PREP (Preparation)
(preparation of)

RN 94711-31-6 HCPLUS

CN Benzenesulfonamide, 4-amino-N-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-
(CA INDEX NAME)

L41 ANSWER 33 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1964:3140 HCPLUS Full-text

DOCUMENT NUMBER: 60:3140

ORIGINAL REFERENCE NO.: 60:514h,515a-c

TITLE: Pyrazoles. XXVII. The synthesis and the antibacterial effect of sulfanilamidopyrazoles

AUTHOR(S): Padeiskaya, E. N.; Grandberg, I. I.; Pershin, G. N.; Kost, A. N.; Ovseneva, L. G.; Ting, Wei-P'i

SOURCE: Vestnik Moskovskogo Universiteta, Seriya 2: Khimiya (1963), 18(1), 69-73

DOCUMENT TYPE: CODEN: VMUKA5; ISSN: 0579-9384

LANGUAGE: Journal

DOCUMENT TYPE: Unavailable

ED Entered STN: 22 Apr 2001

GI For diagram(s), see printed CA Issue.

AB cf. CA 58, 4537f. A solution of 7.6 g. NaNO2 in 25 cc. H2O was treated with a solution of 3.2 g. 96% N2H4H2O (I) in 5 cc. AcOH at <5° and the mixture added to 10 g. Ac2CH2 in 30 cc. AcOH to give II (R = H, R' = NO), m. 125° (benzene),

after 4 hrs. in 93.6% yield. II (R' = NO) were prepared similarly (R, % yield, and m.p. given): Ph, 86, 96° (MeOH); CH2Ph, 84, 54° (benzene-petr. ether); (CH₂)₂Ph, 89, 64° (MeOH); iso-Pr, 89, 104° (petr. ether). When II (R = H, R' = NO, 12.5 g.) in 30 cc. MeOH was dropped into a mixture of 40 cc. I and 1 g. skeletal Ni in 30 cc. boiling MeOH and the mixture boiled for 6 hrs., the product was II (R = H, R' = NH₂), m. 201-2° [dipicrate, m. 152° (MeOH)], in 91% yield. II (R' = NH₂) were prepared similarly [R, % yield, m.p. (Et₂O), and m.p.s. of picrate and dipicrate given]: Ph, 61.5, 66° (hydrate), 118° (MeOH), -; CH₂Ph, 62.5, 74°, oil, -; (CH₂)₂Ph, 57.5, 84°, oil, -; iso-Pr, 87.5, 59°, -; 198° (MeOH). II (R' = p-HNC₆H₄SO₂NH) were prepared from II (R' = NH₂) (CA 56, 4746b) (R, % yield, and m.p. given): Ph, 61, 206°; CH₂Ph, 60, 211°; (CH₂)₂Ph, 77.5, 252°; iso-Pr, 84, 121°. Of 18 sulfanilamidopyrazoles studied *in vitro* and *in vivo*, 1-phenyl-3-methyl-5-sulfanilamidopyrazole, 1-phenyl-3-sulfanilamidopyrazole, and 3-phenyl-5-sulfanilamidopyrazole have significant bacteriostatic activity *in vitro*.


IT 94711-31-6P, Sulfanilamide,

N1-(3,5-dimethyl-1-phenylpyrazol-4-yl)-

RL: PREP (Preparation)
(preparation of)

RN 94711-31-6 HCPLUS

CN Benzenesulfonamide, 4-amino-N-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-
(CA INDEX NAME)



L41 ANSWER 34 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1963:53211 HCPLUS [Full-text](#)
 DOCUMENT NUMBER: 58:53211
 ORIGINAL REFERENCE NO.: 58:9046b-f
 TITLE: Sulfanilamide derivatives. IV. Some new sulfanilamides
 of 4-amino-1-phenylpyrazole
 AUTHOR(S): Alberti, C.; Tironi, C.
 CORPORATE SOURCE: Univ. Pavia, Italy
 SOURCE: Farmaco, Edizione Scientifica (1962), 17,
 460-7
 CODEN: FRPSAX; ISSN: 0430-0920
 DOCUMENT TYPE:
 LANGUAGE: Journal
 Unavailable
 ED Entered STN: 22 Apr 2001
 GI For diagram(s), see printed CA Issue.
 AB Influence on the antibacterial activity by the introduction of a methoxy group
 into the benzene ring of N1-(1-phenyl-4-pyrazolyl)sulfanilamide was studied.
 o-Methoxyphenylhydrazine (I) (13.8 g.) suspended in 20 cc. iso-PrOH, treated

with 25 cc. iso-PrOH saturated with HCl gas, and the precipitate filtered off and crystallized from absolute EtOH and Et2O yielded 70% I.HCl (II), m. 158-60°. II (17.5 g.) dissolved in 20 cc. 80% EtOH, treated portionwise with stirring with 15.7 g. Na nitromalonaldehyde, and the mixture heated on steam bath 1.5 hrs. yielded 90% 4-nitro-1-o-methoxyphenyl-pyrazole (III), m. 85-7° (EtOH). III (11 g.) in 200 cc. EtOH treated with 12 g. N2H4.H2O, the mixture refluxed 6-8 hrs. in presence of 0.5 g. Pd-C, the catalyst filtered off, the solvent evaporated in vacuo, and the residue suspended in H2O and crystallized from EtOH yielded 85% 4-amino-1-o-methoxyphenylpyrazole (IV), m. 100-1°.c IV (9.5 g.) in 30 cc. anhydrous pyridine, treated portionwise below 40-50° with 11.3 g. p-acetylaminobenzenesulfonyl chloride, the mixture heated on steam bath for 30 min., cooled, poured into ice containing 100 cc. 2N HCl, and the precipitate filtered off and crystallized from aqueous EtOH yielded 90% N1-(1-o-methoxyphenyl-4-pyrazolyl)-N4-acetylsulfanilamide (V), m. 220-1°. V(7.7g.) saponified with 80cc. 5% NaOH by refluxing 3hrs. yielded 95% N1-(1-o-methoxyphenyl-4-pyrazolyl)sulfanilamide (VI), m. 176-7° (aqueous EtOH). The following compds. were synthesized (in parenthesis, the solvent of crystallization and % yield given): m-methoxyphenylhydrazine-HCl, m. 140-1° (absolute EtOH and Et2O, 50); 4-nitro-1-(m-methoxyphenyl)pyrazole, m. 130-1° (EtOH, 70); 4-amino-1-(m-methoxyphenyl)pyrazole, m. 50-1° (gasoline, 95); N1-(1-m-methoxyphenyl-4-pyrazolyl)-N4-acetylsulfanilamide, m. 190-1° (aqueous EtOH, 50); N1-(1-m-methoxyphenyl-4-pyrazolyl)sulfanilamide (VII), m. 137-8° (aqueous EtOH, 80); p-methoxyphenylhydrazine-HCl, m. 160-1° (absolute EtOH and Et2O, 85); 4-nitro-1-(p-methoxyphenyl)pyrazole, m. 147-8° (EtOH, 95); 4-amino-1-(p-methoxyphenyl)pyrazole, m. 120-1° (H2O 90); N1-(1-p-methoxyphenyl-4-pyrazolyl)-N4 acetylsulfanilamide, m. 183-4° (aqueous EtOH, 90); N1-(1-p-methoxyphenyl-4-pyrazolyl)sulfanilamide (VIII), m. 181-2° (aqueous EtOH, 80). Expts. in vitro showed that VI and VII were active against *S. aureus* at the concentration of 10 γ/cc., while VII at the concentration of 30 γ/cc. VI, VII and VIII were active against *E. coli* at the concentration of 30 γ/cc.

IT 94571-61-6P, Sulfanilamide, N1-[1-(m-methoxyphenyl)pyrazol-4-yl]-

94571-63-8P, Sulfanilamide, N1-[1-(o-methoxyphenyl)pyrazol-4-yl]-

94571-65-0P, Sulfanilamide, N1-[1-(p-methoxyphenyl)pyrazol-4-yl]-

95157-14-5P, Acetanilide, 4'-(1-(m-methoxyphenyl)pyrazol-4-

yl)sulfamoyl]- 98658-70-9P, Acetanilide,

4'-(1-(p-methoxyphenyl)pyrazol-4-yl)sulfamoyl]- 98742-04-2P,


Acetanilide, 4'-(1-(o-methoxyphenyl)pyrazol-4-yl)sulfamoyl]-

RL: PREP (Preparation)


(preparation of)

RN 94571-61-6 HCPLUS


CN Benzenesulfonamide, 4-amino-N-[1-(3-methoxyphenyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 94571-63-8 HCPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(2-methoxyphenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




RN 94571-65-0 HCPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(4-methoxyphenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




RN 95157-14-5 HCPLUS
CN Acetamide, N-[4-[[1-(3-methoxyphenyl)-1H-pyrazol-4-
yl]amino]sulfonyl]phenyl]- (CA INDEX NAME)



RN 98658-70-9 HCPLUS
CN Acetamide, N-[4-[[1-(4-methoxyphenyl)-1H-pyrazol-4-yl]amino]sulfonyl]phenyl- (CA INDEX NAME)




RN 98742-04-2 HCPLUS
CN Acetamide, N-[4-[[1-(2-methoxyphenyl)-1H-pyrazol-4-yl]amino]sulfonyl]phenyl- (CA INDEX NAME)




L41 ANSWER 35 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1963:53210 HCPLUS Full-text
 DOCUMENT NUMBER: 58:53210
 ORIGINAL REFERENCE NO.: 58:9045a-h,9046a-b
 TITLE: Sulfanilamide derivatives. III. Some new compounds of 3-amino-2-phenylpyrazole and 5-amino-3-methyl-1-phenylpyrazole
 AUTHOR(S): Alberti, C.; Tironi, C.
 CORPORATE SOURCE: Univ. Pavia, Italy
 SOURCE: Farmaco, Edizione Scientifica (1962), 17, 443-59
 DOCUMENT TYPE: FRPSAX; ISSN: 0430-0920
 LANGUAGE: Unavailable
 ED Entered STN: 22 Apr 2001
 AB cf. ibid. 16, 557-70(1961); CA 58, 5658a. Various new derivs. were synthesized and pharmacol. studies on their bacteriostaticity were also carried out. o-Methoxyphenylhydrazine (I) (13.8 g.), treated with 5.3 g. CH₂:CHCN (II) in presence of 5% choline hydrate, the mixture heated 1 hr. on steam bath, the separated oil boiled 5 min. with 20 cc. concentrate HCl and 200 cc. H₂O, the solution made alkaline with 10% NaOH and finally the precipitate filtered and crystallized from C₆H₆-ligroine yielded 50% 3-amino-1-(o-methoxyphenyl)-2-pyrazoline (III), m. 98-9°. III (1.9 g.) dissolved in 20 cc. toluene, 2 drops piperidine added, the solution treated with 1.5 g. m-nitrobenzaldehyde (IV) in 1.5 cc. toluene, heated 3 hrs. on a steam bath, and the precipitate filtered off and crystallized from C₆H₆ yielded 77% 3-(m-nitrobenzylideneamino)-1-(o-methoxyphenyl)-2-pyrazoline (V), red needles, m. 184-5°. V (3.2 g.) suspended in 100 cc. Me₂CO, treated with 2 cc. 2% MnSO₄ and 2 cc. Ca(OH)₂ to pH 7-8, the temperature raised to 30-40° with stirring, 2.1 g. KMnO₄ added, the mixture stirred at this temperature 4-5 hrs., some drops H₂O₂ added, MnO₂ filtered off, the organic phase evaporated in vacuo, and the precipitate crystallized from C₆H₆ yielded 71% 3-(m-nitrobenzoylamino)-1-(o-methoxyphenyl)pyrazole (VI), m. 117-18°. VI (3.3 g.) refluxed 3 hrs. with 20cc. EtOH and 20 cc. concentrated HCl, treated with C, EtOH distilled in vacuo, aqueous phase made alkaline with 10% NaOH, extracted with Et₂O, Et₂O evaporated and the residue crystallized from gasoline yielded 90% 3-amino-1-(o-methoxyphenyl)pyrazole (VII), m. 74-5°. Condensing VII with m-nitrobenzoyl chloride in pyridine gave VI. VII (1.9 g.) in 30 cc. anhydrous pyridine, treated dropwise with 2.3 g. p-acetamidobenzenesulfonic add (VIII), and the mixture refluxed 1 hr., cooled at room temperature, and poured into ice containing 100 cc. 2N HCl, yielded 50% N1-[1-(o-methoxyphenyl)-3-

pyrazolyl]-N4-acetylsulfanilamide (IX), m. 218-20°. IX (3.6 g.) in 50 cc. 5% NaOH, refluxed 2 hrs., cooled, the solution acidified with glacial AcOH and the precipitate filtered off and crystallized from aqueous EtOH yielded 70% N1-[1-(o-methoxyphenyl)-3-pyrazolyl]sulfanilamide (X), m. 185-6°. III (1.9 g.) dissolved in 40 cc. anhydrous pyridine, treated dropwise with 5.5 g. chloride of VIII below 65°, then the temperature raised to 95° for 1 hr., the mixture cooled and poured into ice containing 400 cc. 2N HCl, and the precipitate filtered off and saponified as for IX yielded 74% X. Na (0.8 g.) dissolved in 20 cc. anhydrous BuOH, the solution treated with stirring dropwise with 13.8 g. m-methoxyphenylhydrazine (XI), kept 15 min. at room temperature, treated with 5.8 g. II, refluxed 6 hrs., the solvent evaporated in vacuo, residue dissolved in H2O, the solution extracted with Et2O, and the Et2O dried on Na2SO4 and finally evaporated yielded 50% 3-amino-1-(m-methoxyphenyl)-2-pyrazoline (XII), m. 127-8°. Condensing 1.9 g. XII with 1.5 g. IV as for V gave 80% 3-(m-nitrobenzylidenamino)-1-(m-methoxyphenyl)-2-pyrazoline (XIII), red needles, m. 178-9°. Oxidation of XIII (3.2 g.) with KMnO4 as for V yielded 80% 3-(m-nitrobenzylamino)-1-(m-methoxyphenyl)pyrazole (XIV), m. 135-6° (aqueous EtOH). XIV was obtained also condensing 3-amino-1-(m-methoxyphenyl)-pyrazole (XV) with m-nitrobenzoyl chloride. XIV (3.4 g.) in 40 cc. EtOH, treated with 40 cc. concentrated HCl, refluxed 3 hrs. and then the mixture treated as for VII yielded 70% XV, m. 70-1°. Condensation of 1.9 g. XV with 2.3 g. VIII as for IX gave N1-[1-(m-methoxyphenyl)-3-pyrazolyl]-N4-acetylsulfanilamide (XVI), m. 194-5° (aqueous EtOH), in 90% yield. XVI (3.6 g.) saponified as for X with 5% NaOH gave 2.2 g. N1-[1-(m-methoxyphenyl)-3-pyrazolyl]sulfanilamide (XVII), m. 174-5°. I (13.8 g.) in 30 cc. 50% AcOH, treated with 8 g. MeC:(NH)CH2CN (XVIII), the mixture heated 10 min. on steam bath, cooled, allowed to stand at room temperature, and the precipitate filtered off and washed with H2O yielded 75-80% o-methoxyphenylhydrazone of the β -oxopropio-nitrile (XIX), m. 92-3°. XIX (10.2 g.) in 5 cc. 6N HCl, heated 30 min. on steam bath, cooled, and the precipitate filtered off and crystallized from absolute EtOH and anhydrous Et2O yielded 85% 5-amino-1-(o-methoxyphenyl)-3-methylpyrazole-HCl, m. 217-18°, from which the base (XX), m. 105-6°, was obtained by hydrolysis with NH3 in 70-75% yield. XX (10.2 g.) in 50 cc. anhydrous pyridine, treated dropwise with stirring with 11.5 g. chloride of VIII, the mixture heated 30 min. on steam bath, cooled, poured into ice containing 100 cc. 2N HCl, and the precipitate purified by dissolution in 5% NaOH and repprt. in dilute HCl yielded 70% N1-[1-(o-methoxyphenyl)-3-methyl-5-pyrazolyl]-N4-acetylsulfanilamide (XXI), m. 177-8°, which saponified with 5% NaOH as for XVII gave N1-[1-(o-methoxyphenyl)-3-methyl-5-pyrazolyl]sulfanilamide (XXII), m. 236-7°. Treating 13.8 g. XI with 8 g. XVII similarly as for XIX gave 80% m-methoxyphenylhydrazone of β -oxopropionitrile (XXIII), m. 111-12°. Treating XXIII in the same manner as for XX, XXI, and XXII gave 5-amino-1-(m-methoxyphenyl)-3-methylpyrazole, m. 112-13° (gasoline) (HCl salt m. 183-4°), N1-[1-(m-methoxyphenyl)-3-methyl-5-pyrazolyl]-N4-acetylsulfanilamide, m. 156-7° (aqueous EtOH), and N1-[1-(m-methoxyphenyl)-3-methyl-5-pyrazolyl]-sulfanilamide (XXIV), m. 197-8°, in 80, 75, and 80% yield, resp. Similarly the following compds. were synthesized: p-methoxyphenylhydrazone of β -oxopropionitrile, m. 100-1° (80-90% yield from EtOH), 5-amino-1-(p-methoxyphenyl)-3-methylpyrazole, m. 104-5° (85% yield, HCl salt m. 215-16°), N1-[1-p-methoxyphenyl-3-methyl-5-pyrazolyl]-N4-acetylsulfanilamide, m. 200-1° (75% yield from aqueous EtOH), and N1-[1-p-methoxyphenyl-3-methyl-5-pyrazolyl]sulfanilamide (XXV), m. 186-7° (84% yield from aqueous EtOH). All the synthesized sulfanilamides were active against *Staphylococcus aureus* at the concentration of 10 γ /cc. Expts. in vitro showed that XVII was active against *Escherichia coli* at the concentration of 10 γ /cc., X and XV at the concentration of 30 γ /cc. and XXI and XXIV at the concentration of 50 γ /cc.


(Derived from data in the 7th Collective Formula Index (1962-1966))
RN 94571-61-6 HCPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(3-methoxyphenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




RN 94571-63-8 HCPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(2-methoxyphenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




RN 94571-65-0 HCPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(4-methoxyphenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




RN 95157-14-5 HCAPLUS
CN Acetamide, N-[4-[(1-(3-methoxyphenyl)-1H-pyrazol-4-yl)amino]sulfonyl]phenyl- (CA INDEX NAME)



RN 98658-70-9 HCAPLUS
CN Acetamide, N-[4-[(1-(4-methoxyphenyl)-1H-pyrazol-4-yl)amino]sulfonyl]phenyl- (CA INDEX NAME)



RN 98742-04-2 HCPLUS
 CN Acetamide, N-[4-[(1-(2-methoxyphenyl)-1H-pyrazol-4-yl)amino]sulfonyl]phenyl- (CA INDEX NAME)




L41 ANSWER 36 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1963:53209 HCPLUS Full-text
 DOCUMENT NUMBER: 58:53209
 ORIGINAL REFERENCE NO.: 58:9044f-h,9045a
 TITLE: Preparation and properties of 2-biphenylpenicillin
 AUTHOR(S): Gourevitch, A.; Holdrege, C. T.; Hunt, G. A.; Minor, W. F.; Flanigan, C. C.; Cheney, L. C.; Lein, J.
 CORPORATE SOURCE: Bristol Labs., Syracuse, NY
 SOURCE: Antibiot. Chemotherapy (1962), 12, 318-24
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 ED Entered STN: 22 Apr 2001
 AB Na 2-biphenylpenicillin monohydrate (I) was prepared from a soln of 48.4 g. 2-biphenylcarbonyl chloride in 100 ml. Me₂CO added to 48.3 g. 6-aminopenicillanic acid, 56.4 g. NaHCO₃, 330 ml. H₂O, and 230 ml. Me₂CO at 5°. The mixture was stirred for 20 min. at 10-13°, extracted with EtOAc, the

aqueous phase layered with EtOAc, and acidified with 42% H3PO4. The aqueous phase was extracted twice with EtOAc and the combined exts. dried with anhydrous Na2SO4, filtered, and treated with a BuOH solution of Na 2-ethylhexanoate (II) to give crystalline I in 72.5% yield, decomposed 173-80°. II was prepared by adding equimolar amts. of NaOH in MeOH to 2-ethyl- hexanoic acid, removing the MeOH in vacuo, dissolving the residue in EtOAc, and stripping in vacuo 4 times. The residue containing II was dissolved in BuOH. I had a typical penicillin spectrum in vitro against various microorganisms and was comparable in activity on a weight basis to 5-methyl-3-phenyl-4-isoxazolylpenicillin (III). I was less active than III against penicillinase-producing staphylococci. I was somewhat more susceptible than III to penicillinase, but considerably less acid stable than III. III protected mice from exptl. infections with penicillinase-producing staphylococci. Blood levels in human subjects following oral administration of I were lower than those obtained with corresponding levels of III.


IT 94571-61-6 94571-63-8 94571-65-0
95157-14-5 98658-70-9 98742-04-2

(Derived from data in the 7th Collective Formula Index (1962-1966))


RN 94571-61-6 HCPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(3-methoxyphenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




RN 94571-63-8 HCPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(2-methoxyphenyl)-1H-pyrazol-4-yl]- (CA
INDEX NAME)




RN 94571-65-0 HCAPLUS
CN Benzenesulfonamide, 4-amino-N-[1-(4-methoxyphenyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 95157-14-5 HCAPLUS
CN Acetamide, N-[4-[[1-(3-methoxyphenyl)-1H-pyrazol-4-yl]amino]sulfonyl]phenyl- (CA INDEX NAME)



RN 98658-70-9 HCPLUS
CN Acetamide, N-[4-[[1-(4-methoxyphenyl)-1H-pyrazol-4-yl]amino]sulfonyl]phenyl- (CA INDEX NAME)



RN 98742-04-2 HCPLUS
CN Acetamide, N-[4-[[1-(2-methoxyphenyl)-1H-pyrazol-4-yl]amino]sulfonyl]phenyl- (CA INDEX NAME)



L41 ANSWER 37 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1960:93857 HCPLUS Full-text

DOCUMENT NUMBER: 54:93857

ORIGINAL REFERENCE NO.: 54:17798c-d

TITLE: Activity of pyrazolesulfonamides

AUTHOR(S): Guarneri, Mario

CORPORATE SOURCE: Univ. Ferrara, Italy

SOURCE: Bollettino Chimico Farmaceutico (1960), 99,

259-62

CODEN: BCFAAI; ISSN: 0006-6648

Journal

DOCUMENT TYPE: Unavailable


ED Entered STN: 22 Apr 2001

AB 1-Phenyl-3-methyl-5-(p-aminophenylsulfonamido)pyrazole has the same bacteriostatic activity as 1-phenyl-5-(p-aminophenylsulfamido)pyrazole, already used therapeutically. The introduction of an amino group into the pyrazole nucleus without changing other substituents leads to the formation of 2 isomers. 1-Phenyl-3-methyl-4-amino-5-(p-aminophenylsulfamido)pyrazole showed the highest activity of all sulfapyrazole derivs. known.


IT 108978-20-7, Sulfanilamide,
N1-[5-amino-3-methyl-1-phenylpyrazol-4-yl]-
(bactericidal activity of)

RN 108978-20-7 HCPLUS

CN Benzenesulfonamide, 4-amino-N-(5-amino-3-methyl-1-phenyl-1H-pyrazol-4-yl)-
(CA INDEX NAME)




L41 ANSWER 38 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1960:23043 HCPLUS Full-text
 DOCUMENT NUMBER: 54:23043
 ORIGINAL REFERENCE NO.: 54:4544e-h
 TITLE: Contribution to the study of pyrazolesulfonamides
 AUTHOR(S): Guaneri, Mario; Duda, Liliana
 CORPORATE SOURCE: Univ. Ferrara, Italy
 SOURCE: Annali di Chimica (Rome, Italy) (1959), 49,
 958-63
 CODEN: ANCRAI; ISSN: 0003-4592
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 ED Entered STN: 22 Apr 2001
 AB cf. C.A. 50, 8605d. Syntheses of 2 isomeric amino(p-aminobenzenesulfonamido)-phenylmethylpyrazoles are described (for pharmacol. testing). 1-Phenyl-3-methyl-5-(p-aminobenzenesulfonamido)pyrazole (I) (6 g.) in 32 cc. 10% NaOH, coupled with PhN2Cl (from 2.26 g. PhNH2), gives 6 g. 1-phenyl-3-methyl-4-phenylazo-5-(p-aminobenzenesulfonamido)pyrazole (II), m. 225°. Hydrolysis of II by concentrated HCl gives 1-phenyl-3-methyl-4-phenylazo-5-aminopyrazole. A suspension of 5 g. II in 37 cc. dilute HCl is treated gradually with 7.5 g. SnCl2 in 15 cc. concentrated HCl, and the solution diluted with 150 cc. H2O, treated with H2S, filtered, concentrated, and brought to pH 6 gives 3 g. 1-phenyl-3-methyl-4-amino-5-(p-aminobenzenesulfonamido)pyrazole, m. 204°, also obtained by reduction of the 4-nitroso compound, m. 238°, which is prepared by nitrosation of I with AmONO in EtOH. 1-Phenyl-3-methyl-4-nitroso-5-aminopyrazole (5 g.) (Mohr, C.A. 3, 1866), heated 10 min. at 70° with 40 cc. Ac2O, then aged 24 hrs. at room temperature, gives the 5-AcNH compound. This (5 g.) added to 50 cc. saturated (NH4)2S, heated a few min. at 100°, filtered, made strongly alkaline, and saturated with NaCl ppts. 5 g. 1-phenyl-3-methyl-4-amino-5-acetamidopyrazole (III), m. 76°; this with Ac2O gives the 4,5-bis(acetamido)pyrazole, m. 233°. A suspension of 4.75 g. III in 30 cc. dioxane treated with 4 cc. pyridine and 4.66 g. p-AcNH₂H₄SO₂Cl, the lower layer drowned on ice, and the precipitate boiled 2 hrs. with 10% NaOH, diluted with H2O, and neutralized with HCl gives 4 g. 1-phenyl-3-methyl-4-(p-aminobenzenesulfonamido)-5-aminopyrazole, m. 198°, also obtained by the action of p-AcNH₂H₄SO₂Cl as above on the 4,5-diamine.
 IT 108978-20-7P, Sulfanilamide,
 N1-[5-amino-3-methyl-1-phenylpyrazol-4-yl]-
 RL: PREP (Preparation)
 (preparation of)
 RN 108978-20-7 HCPLUS
 CN Benzenesulfonamide, 4-amino-N-(5-amino-3-methyl-1-phenyl-1H-pyrazol-4-yl)-
 (CA INDEX NAME)



L41 ANSWER 39 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1942:36379 HCPLUS
 DOCUMENT NUMBER: 36:36379
 ORIGINAL REFERENCE NO.: 36:5658f-h
 TITLE: Aminoarylsulfonamidopyrazolones
 INVENTOR(S): Winnek, Philip S.
 PATENT ASSIGNEE(S): American Cyanamid Co.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2281014	-----	19420428	US 1939-278075	19390608 <--

ED Entered STN: 16 Dec 2001
 AB By reactions such as between a 4-aminopyrazolone and a p-acylamino benzenesulfonyl chloride, products are obtained which may be used as dye intermediates, details being given of the production of: 4-(p-aminophenylsulfonyl)antipyrine; 4-(p-aminophenylsulfonylamo)-2-phenyl-3-methyl-5-pyrazolone; 4-(p-aminophenylsulfonylamo)-1-phenyl-2-ethyl-3-methyl-5-pyrazolone; 4-(o- and m-aminophenylsulfonylamo)-1-phenyl-2-ethyl-3-methyl-5-pyrazolone; 1-methyl-2-(p-aminophenylsulfonylamo-p'-phenyl)-3-methyl-4-(p-aminophenylsulfonylamo)-5-pyrazolone; and the Na formaldehydesulfoxylate derivative of 4-(p-aminophenylsulfonylamo)antipyrine; and general mention is made of the production of salts such as those of the alkali metals, Cu, Au, Pb and Fe.
 IT 858809-68-4P, Sulfanilamide,
 N1-(2,3-dihydro-5-methyl-3-oxo-1-phenyl-4-pyrazolyl)-
 RL: PREP (Preparation)
 (preparation of)
 RN 858809-68-4 HCPLUS
 CN Benzenesulfonamide, 4-amino-N-(2,3-dihydro-5-methyl-3-oxo-1-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)



L41 ANSWER 40 OF 43 HCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1915:6830 HCPLUS Full-text
 DOCUMENT NUMBER: 9:6830
 ORIGINAL REFERENCE NO.: 9:1031a-f
 TITLE: 1-Phenyl-3-methyl-4-amino-5-chloropyrazole and its derivatives
 AUTHOR(S): Michaelis, A.; Bressel, Hans
 CORPORATE SOURCE: Univ. Rostock
 SOURCE: Justus Liebigs Annalen der Chemie (1915), 407, 274-89
 CODEN: JLACBF; ISSN: 0075-4617
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 ED Entered STN: 16 Dec 2001
 AB cf. preceding abstract and Ger. pat., 153.861. 1-Phenyl-3-methyl-4-amino-5-chloropyrazole (A), prepared by treating 25 g. 4-azobenzene- or 4-azotoluene-5-chloropyrazole, suspended in 150 cc. saturated alc. HCl, with 20 g. granulated Zn, warming until solution results, allowing to crystalline for 24 h., and liberating the base with NaOH, compact tables or needles, m. 49°. In the air it darkens and resinifies. CaCl₂ gives a deep red solution in AcOH, dark red in EtOH, changing to green. H₂O₂ gives a red resinous compound, CrO₂ a ruby-red dye. Hydrochloride, needles from H₂O, compact leaflets from alc., m. 222° (decompose). Chloroplatinate fine golden yellow needles, darken 200°, m. 280° (decompose). Picrate, yellow, m. 95°. 4-Benzylidene derivative, slightly yellow needles, m. 72°. 4-p-Nitrobenzylidene derivative, long yellow needles, m. 141°. 4-p-Hydroxybenzylidene derivative, yellow leaflets, m. 100°. 4-p-Methoxybenzylidene derivative, needles, m. 91-2°. 4-Thionyl derivative, slightly yellow compact prisms, m. 128°. 4-Formyl derivative, leaflets, m. 137°. Acetyl derivative, needles, m. 123°. Benzoyl derivative, leaflets, m. 148°. 4-Benzenesulfonyl derivative, prisms, m 154°. Urea derivative, sinters 226°, m. 230°. Monophenylurea, microcyst, powder, m. 216°. Monophenylthiourea, m. 182°. One g. (A), treated with 3 g. MeI and 5 g. MeOH 1.5 h., gave 1-phenyl-3-methyl-4-dimethyl-amino-5-chloropyrazole hydroiodide, small needles, m. 147°. The diazo solution of (A) is very stable, does not evolve N when heated and couples with alkaline phenol solns. after heating. The diazonium chloride does not crystalline, NaOH ppts. a white flaky compound, probably the hydroxide, which gradually forms a brown resin. 1-Phenyl-3-methyl-4-azo-β-naphthol-5-chloropyrazole, red needles, m. 199°. 1-Phenyl-3-methyl-4-azo-5-pyrazolone-5'-chloropyrazole (B), fine, red needles, m. 143°. 4-Azo-5,5'-dichloropyrazole (C), by heating (B) with POCl₃ at 140°, fine yellow needles, m. 226°. Me chloride derivative, prepared by heating 1-phenyl-3-methyl-4-ketopyrazolone antipyrylhydrazone (Knorr and Stolz, Ann.

293, 69(1896)) with 1.5 mols. POC13 4 h. at 150°, yellow needles with 1 mol. H₂O, m. 220°. When melted this splits off H₂O and MeCl, giving (C).
 IT 861529-41-1P, Benzenesulfonamide,
 N-(5-chloro-3-methyl-1-phenyl-4-pyrazolyl)-
 RL: PREP (Preparation)
 (preparation of)
 RN 861529-41-1 HCPLUS
 CN Benzenesulfonamide, N-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)- (CA
 INDEX NAME)



L41 ANSWER 41 OF 43 MARPAT COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 149:97688 MARPAT Full-text
 TITLE: Ectoparasiticidal formulations containing
 arylpyrazoles and pyrethroids
 INVENTOR(S): Sirinyan, Kirkor; Turberg, Andreas
 PATENT ASSIGNEE(S): Bayer HealthCare A.-G., Germany
 SOURCE: PCT Int. Appl., 29pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008080542	A2	20080710	WO 2007-EP10981	20071214
WO 2008080542	A3	20080828		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
 GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
 KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA


DE 102006061538 A1 20080703 DE 2006-10200606153820061227

PRIORITY APPLN. INFO.: DE 2006-10200606153820061227

AB Agents for controlling parasites on animals contain an N-arylpypyrazole and a pyrethroid in a formulation containing an aliphatic, cyclic carbonate and an aliphatic cyclic or acyclic polyether. Thus, a liquid formulation containing 5-amino-4-[(trifluoromethyl)sulfinyl]-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-3-(thiocarbamoyl)pyrazole 10.00 g, flumethrin 0.24 g, and the synergist MGK 264 5.00 g/100 mL along with dipropylene glycol monomethyl ether, propylene carbonate, propylene glycol octanoate/decanoate

and other ingredients, when applied at 0.15 mL/kg to cats, had an efficacy of 100% against Ctenocephalides felis on day 14 of infestation.

MSTR 1



G1 = 17

$\text{^15N} - \text{^12C}$

G2 = F
G3 = CF3
G5 = CN
G6 = 50

$\text{^5B} - \text{^10C}$

G9 = 52

$\text{^5N} - \text{^10C}$

G10 = alkyl <containing 1-4 C>
(opt. substd. by 1 or more G33) /
alkylsulfonyl <containing 1-4 C>


G33 = F
Patent location: disclosure

L41 ANSWER 42 OF 43 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 149:97689 MARPAT Full-text
TITLE: Phenylpyrazole formulations for controlling parasites
on animals
INVENTOR(S): Sirinyan, Kirkor; Turberg, Andreas
PATENT ASSIGNEE(S): Bayer HealthCare A.-G., Germany
SOURCE: PCT Int. Appl., 34pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008080541	A1	20080710	WO 2007-EP10980	20071214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102006061537	A1	20080703	DE 2006-102006061537/20061227	DE 2006-102006061537/20061227
PRIORITY APPLN. INFO.:				
AB Novel agents for controlling parasites on animals contain an N-phenylpyrazole in a formulation containing aliphatic cyclic carbonates. Thus, a liquid formulation (100 mL) containing 5-amino-4-[(trifluoromethyl)sulfinyl]-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-3-(thiocarbamoyl)pyrazole 10.0, diethylene glycol monoethyl ether 57.7, propylene carbonate 40.0, propylene glycol octanoate/decanoate 5.0 along with BHT and BHA, when applied at 0.15 mL/kg to cats, had an efficacy of 100% against Ctenocephalides felis on cats reinfested after ≤35 days.				

MSTR 1



G1 = 17

17—G2

G2 = F
 G3 = CF₃
 G5 = CN
 G6 = 50

503—G10

G9 = 52

52—G10

G10 = alkyl <containing 1-4 C>
 (opt. substd. by 1 or more G33) /
 alkylsulfonyl <containing 1-4 C>

G33 = F

Patent location: disclosure

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L41 ANSWER 43 OF 43 MARPAT COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 143:347161 MARPAT Full-text
 TITLE: Preparation of N-(1-arylpyrazol-4-yl) sulfonamides as parasiticides
 INVENTOR(S): Critcher, Douglas James; Lauret, Christelle; Walshe, Nigel Derek Arthur
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl., 158 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090313	A1	20050929	WO 2005-IB597	20050307
W:	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005223483	A1	20050929	AU 2005-223483	20050307
CA 2560510	A1	20050929	CA 2005-2560510	20050307
EP 1735284	A1	20061227	EP 2005-708697	20050307
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2007529497	T	20071025	JP 2007-503430	20050307
US 20080261940	A1	20081023	US 2006-593133	20061130
PRIORITY APPLN. INFO.:			GB 2004-6137	20040318
			US 2004-571415P	20040513
			WO 2005-IB597	20050307

OTHER SOURCE(S): CASREACT 143:347161

AB The title compds. I [R1 = (un)substituted Ph, heteroaryl; R2 = H, halo, CN, etc.; R3 = alkyl, haloalkyl, alkenyl, etc.; R4 = H, alkyl, haloalkyl, etc.; or R3 and R4 taken together with the N and S atoms to which they are attached form a 4-7 membered ring; R5 = H, OH, halo, etc.] or a pharmaceutically, veterinarianly or agriculturally acceptable salts or solvates thereof, useful as parasiticides, were prepared Thus, reacting N-(5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl)methanesulfonamide with 2,3-difluoroethyl trifluoromethanesulfonate in the presence of K₂CO₃ in MeCN afforded II. The flea membrane feed test is used to measure the biol. activities of the compds. I. All the exemplified compds. I have flea ED₅₀ of less than 100 µg/mL.

MSTR 1



G1 = Ph (opt. substd. by 1 or more G49)
 G3 = F
 G6 = CN / 24 / 36 / 38

2 G7—G8 3 G12—G14 3 G17—3 G18

G7 = alkylene <containing 1-3 C>
 (opt. substd. by 1 or more G3)
 G14 = 34

3 G7—G15

G18 = 40

4 G12—G14

G22 = 55 / 57 / 60 / 62 / Me

5 G7—G8 5 G7—G4—G5 6 G12—G14 6 G7—G18

G25 = 72

78—G26

G26 = 79 / 81 / 91 / 97

797—G28 897—G29 9730—G218 9531—G24

G30 = 95-72 96-92

957—G24

G31 = 99-72 100-98

997—G24

G32 = 6

G25—G02—G22

G34 = 119

1939—G41

G41 = 139

1938—G18

G49 = F / CF3

Patent location:

Note:

claim 1
or pharmaceutically, veterinarily or agriculturally
acceptable salts or solvates

REFERENCE COUNT:

18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Search History

L1 2 SEA SPE=ON ABB=ON PLU=ON US2006-593133/APPS
SEL RN

FILE 'REGISTRY' ENTERED AT 13:15:04 ON 16 APR 2009

L2 257 SEA SPE=ON ABB=ON PLU=ON (100-39-0/B1 OR 100-52-7/B1 OR
1027267-86-2/B1 OR 1034344-02-9/B1 OR 1034346-91-2/B1 OR
1034348-47-4/B1 OR 1034354-48-7/B1 OR 106-95-6/B1 OR 108-00-9/B
I OR 113293-71-3/B1 OR 118431-88-2/B1 OR 120068-79-3/B1 OR
120068-80-6/B1 OR 120113-87-9/B1 OR 120507-97-3/B1 OR 126200-24
-6/B1 OR 13918-92-8/B1 OR 139631-62-2/B1 OR 142-25-6/B1 OR
145758-05-0/B1 OR 148836-73-1/B1 OR 1489-69-6/B1 OR 149757-20-0
/B1 OR 149757-21-1/B1 OR 154807-46-2/B1 OR 1633-82-5/B1 OR
1633-84-7/B1 OR 165114-85-2/B1 OR 1759-53-1/B1 OR 188539-59-5/B
I OR 188539-78-8/B1 OR 18997-19-8/B1 OR 19225-92-4/B1 OR
1939-99-7/B1 OR 202827-55-2/B1 OR 2038-03-1/B1 OR 22236-10-8/B1
OR 27578-60-5/B1 OR 288-88-0/B1 OR 2993-24-0/B1 OR 349-88-2/B1
OR 35166-37-1/B1 OR 371917-17-8/B1 OR 372-09-8/B1 OR 372-16-7/
BI OR 3870-89-2/B1 OR 40497-11-8/B1 OR 4399-47-7/B1 OR
459-46-1/B1 OR 503-29-7/B1 OR 52147-97-4/B1 OR 5344-27-4/B1 OR
55401-97-3/B1 OR 6283-71-2/B1 OR 6705-33-5/B1 OR 7051-34-5/B1
OR 7154-73-6/B1 OR 74427-22-8/B1 OR 856226-78-3/B1 OR 856226-79
-4/B1 OR 856226-94-3/B1 OR 856226-98-7/B1 OR 865832-30-0/B1 OR
865832-31-1/B1 OR 865832-32-2/B1 OR 865832-33-3/B1 OR 865832-34
-4/B1 OR 865832-35-5/B1 OR 865832-36-6/B1 OR 865832-37-7/B1 OR
865832-38-8/B1 OR 865832-39-9/B1 OR 865832-40-2/B1 OR 865832-41
-3/B1 OR 865832-42-4/B1 OR 865832-43-5/B1 OR 865832-44-6/B1 OR
865832-45-7/B1 OR 865832-46-8/B1 OR 865832-47-9/B1 OR 865832-48
-0/B1 OR 865832-49-1/B1 OR 865832-50-4/B1 OR 865832-51-5/B1 OR
865832-52-6/B1 OR 865832-53-7/B1 OR 865832-54-8/B1 OR 865832-55
-9/B1 OR 865832-56-0/B1 OR 865832-57-1/B1 OR 865832-58-2/B1 OR
865832-59-3/B1 OR 865832-60-6/B1 OR 865832-61-7/B1 OR 865832-62
-8/B1 OR 865832-63-9/B1 OR 865832-64-0/B1 OR 865832-65-1/B1 OR
865832-66-2/B1 OR 865832-67-3/B1 OR 865832-68-4/B1 OR 865832-69
-5/B1 OR 865832-70-8/B1

L3 204 SEA SPE=ON ABB=ON PLU=ON L2 AND C3N2/EA

L4 154 SEA SPE=ON ABB=ON PLU=ON L3 AND S>=1 AND O>=2

L5 STRUCTURE uploaded

L6 50 SEA SSS SAM L5

L7 4 SEA SPE=ON ABB=ON PLU=ON L6 AND L2

L8 2558 SEA SSS FUL L5

L9 STRUCTURE uploaded

L10 50 SEA SSS SAM L9

L11 4 SEA SPE=ON ABB=ON PLU=ON L10 AND L2

L12 2562 SEA SSS FUL L9

L13 133 SEA SPE=ON ABB=ON PLU=ON L12 AND L2

L14 STRUCTURE uploaded

L15 8 SEA SUB=L12 SSS SAM L14

L16 4 SEA SPE=ON ABB=ON PLU=ON L15 AND L2

L17 263 SEA SUB=L12 SSS FUL L14

FILE 'HCAPLUS' ENTERED AT 13:24:17 ON 16 APR 2009

L18 42 SEA SPE=ON ABB=ON PLU=ON L17

FILE 'REGISTRY' ENTERED AT 13:25:43 ON 16 APR 2009

L19 STRUCTURE uploaded

L20 0 SEA SUB=L12 SSS SAM L19
 L21 2 SEA SUB=L12 SSS FUL L19

FILE 'HCAPLUS' ENTERED AT 13:26:44 ON 16 APR 2009
 L22 1 SEA SPE=ON ABB=ON PLU=ON L21
 L23 24 SEA SPE=ON ABB=ON PLU=ON CRITCHER D?/AU
 L24 28 SEA SPE=ON ABB=ON PLU=ON WALSHE N?/AU
 L25 29 SEA SPE=ON ABB=ON PLU=ON LAURET C?/AU
 L26 1 SEA SPE=ON ABB=ON PLU=ON (L23 OR L24 OR L25) AND (L18 OR L22)
 L27 42 SEA SPE=ON ABB=ON PLU=ON (L18 OR L22) AND (PRY<=2006 OR PY<=2006 OR AY<=2006)

FILE 'WPIX' ENTERED AT 13:28:48 ON 16 APR 2009
 L28 0 SEA SSS SAM L19
 L29 2 SEA SSS FUL L19
 L30 1 SEA SPE=ON ABB=ON PLU=ON L29/DCR
 L31 1 SEA SPE=ON ABB=ON PLU=ON (L23 OR L24 OR L25) AND L30

FILE 'BEILSTEIN' ENTERED AT 13:29:30 ON 16 APR 2009
 L32 0 SEA SPE=ON ABB=ON PLU=ON L21
 L33 0 SEA SPE=ON ABB=ON PLU=ON L21

FILE 'MARPAT' ENTERED AT 13:29:44 ON 16 APR 2009
 L34 STRUCTURE uploaded
 L35 STRUCTURE uploaded
 L36 1 SEA SSS SAM L35
 L37 3 SEA SSS FUL L35

FILE 'HCAPLUS, WPIX' ENTERED AT 13:33:38 ON 16 APR 2009
 L38 1 DUP REM L26 L31 (1 DUPLICATE REMOVED)

FILE 'HCAPLUS' ENTERED AT 13:34:07 ON 16 APR 2009
 L39 41 SEA SPE=ON ABB=ON PLU=ON L27 NOT L26

FILE 'WPIX' ENTERED AT 13:34:27 ON 16 APR 2009
 L40 0 SEA SPE=ON ABB=ON PLU=ON L30 NOT L31

FILE 'HCAPLUS, MARPAT' ENTERED AT 13:34:58 ON 16 APR 2009
 L41 43 DUP REM L39 L40 L37 (1 DUPLICATE REMOVED)